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ABSTRACT 
 
CD4 T cells and B cells are cells associated with the adaptive immune system. 
The adaptive immune system is designed to mount a rapid antigen-specific response to 
pathogens by way of clonal expansions of T and B cells bearing discrete antigen-specific 
receptors. During viral infection, interactions between CD4 T cells and B cells occur in a 
dynamic process, where B cells that bind to the virus internalize and degrade virus 
particles. The B cells then present viral antigens to virus-specific CD4 T cells that 
activate the B cells and cause them to proliferate and differentiate into virus-specific 
antibody-secreting cells. Yet, non-specific hypergammaglobulinemia and the production 
of self-reactive antibodies occur during many viral infections, and studies have suggested 
that viral antigen-presenting B cells may become polyclonally activated by CD4 T cells 
in vivo in the absence of viral engagement of the B cell receptor. This presumed 
polyclonal B cell activation associated with virus infection is of great medical interest 
because it may be involved in the initiation of autoimmunity or contribute to the long-
term maintenance of B cell memory.  
In order to directly examine the interactions that occur between T cells and B 
cells, I asked what would happen to a polyclonal population of B cells that are presenting 
viral antigens, if they were transferred into virus-infected hosts. I performed these studies 
in mice using the well-characterized lymphocytic choriomeningitis virus (LCMV) model 
of infection. I found that the transferred population of antigen-presenting B cells had two 
fates. Some antigen-expressing B cells were killed in vivo by CD4 T cells in the first day 
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after transfer into LCMV-infected hosts. However, B cells that survived the cytotoxicity 
underwent a dynamic polyclonal activation manifested by proliferation, changes in 
phenotype, and antibody production. 
The specific elimination of antigen-presenting B cells following adoptive transfer 
into LCMV-infected hosts is the first evidence that MHC class II-restricted killing can 
occur in vivo during viral infection. This killing was specific, because only cells 
expressing specific viral peptides were eliminated, and they were only eliminated in 
LCMV-infected mice. In addition to peptide specificity, killing was restricted to MHC 
class II high cells that expressed the B cell markers B220 and CD19. Mice depleted of 
CD4 T cells prior to adoptive transfer did not eliminate virus-specific targets, suggesting 
that CD4 T cells are required for this killing. I found that CD4 T cell-dependent 
cytotoxicity cannot be solely explained by one mechanism, but Fas-FasL interactions and 
perforin are mechanisms used to induce lysis. 
Polyclonal B cell activation, hypothesized to be the cause of virus-induced 
hypergammaglobulinemia, has never been formally described in vivo. Based on previous 
studies of virus-induced hypergammaglobulinemia, which showed that CD4 T cells were 
required and that hypergammaglobulinemia was more likely to occur when virus grows 
to high titer in vivo, it was proposed that the B cells responsible for 
hypergammaglobulinemia may be expressing viral antigens to virus-specific CD4 T cells 
in vivo. CD4 T cells would then activate the B cells. However, because the antibodies 
produced during hypergammaglobulinemia are predominantly not virus-specific, non-
virus-specific B cells must be presenting viral antigens in vivo. 
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In my studies, the adoptively transferred B cells that survived the MHC class II-
restricted cytotoxicity became polyclonally activated in LCMV-infected mice. Most of 
the surviving naïve B cells presenting class II MHC peptides underwent an extensive 
differentiation process involving both proliferation and secretion of antibodies. Both 
events required CD4 cells and CD40/CD40L interactions to occur but B cell division did 
not require MyD88-dependent signaling, type I interferon signaling, or interferon γ 
signaling within B cells. No division or activation of B cells was detected at all in virus-
infected hosts in the absence of cognate CD4 T cells and class II antigen. B cells taken 
from immunologically tolerant donor LCMV carrier mice with high LCMV antigen load 
became activated following adoptive transfer into LCMV-infected hosts, suggesting that 
B cells can present sufficient antigen for this process during a viral infection. A 
transgenic population of B cells presenting viral antigens was also stimulated to undergo 
polyclonal activation in LCMV-infected mice. Due to the high proportion of B cells 
stimulated by virus infection and the fact that transgenic B cells can be activated in this 
manner, I conclude that virus-induced polyclonal B cell activation is independent of B 
cell receptor specificity. This approach, therefore, formally demonstrates and quantifies a 
virus-induced polyclonal proliferation and differentiation of B cells which can occur in a 
B cell receptor-independent manner.  
By examining the fate of antigen-presenting B cells following adoptive transfer 
into LCMV-infected mice, I have been able to observe dynamic interactions between 
virus-specific CD4 T cells and B cells during viral infection. Adoptive transfer of 
antigen-presenting B cells results in CD4 T cell-mediated killing and polyclonal 
 ix
activation of B cells during LCMV infection. Studies showing requirements for CD4 T 
cells or MHC class II to control viral infections must now take MHC class II-restricted 
cytotoxicity into account. Polyclonal B cell activation after viral infection has the 
potential to enhance the maintenance of B cell memory or lead to the onset of 
autoimmune disease.  
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CHAPTER I 
 
INTRODUCTION 
 
This thesis will examine some of the interactions that occur between CD4 T cells 
and B cells during a viral infection. To accomplish this, I performed several adoptive 
transfer studies, where B cells were coated with viral antigens and transferred into virus-
infected hosts. During the course of my thesis, I will show that the transferred population 
of antigen-presenting B cells has two fates. CD4 T cells can eliminate B cells in virus-
infected mice. This major histocompatibility complex (MHC) class II-restricted killing is 
the first evidence of CD4 T cell-dependent cytotoxicity in vivo during viral infection. I 
also show that those B cells that survive killing, somewhat paradoxically, become 
polyclonally activated by CD4 T cells. Polyclonal B cell activation was implicated to be 
the cause of virus-induced hypergammaglobulinemia that is seen after various human and 
murine virus infections. However, my demonstration of virus-induced polyclonal B cell 
activation is the first, and through the approach described herein, I am able to make 
specific conclusions about virus-induced hypergammaglobulinemia and polyclonal B cell 
activation. To examine these processes in detail, I used the well-characterized 
lymphocytic choriomeningitis virus (LCMV) model of virus infection in mice where the 
kinetics of the immune response have been studied extensively, the antigenic MHC class 
II epitopes are defined, and where hypergammaglobulinemia has been previously 
observed.  
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 A. The LCMV model of viral infection.  LCMV infection of mice is perhaps the 
best studied model of viral infection. Studies of mice infected with LCMV have allowed 
researchers to define many aspects of the mammalian immune system. These definitions 
have translated across other models of infection and have lead to a deeper understanding 
of our own immune response.  Concepts such as immune tolerance, virus-induced 
immunopathology, immune complex disease, T cell recognition of antigen-MHC 
complexes, T cell education in the thymus, NK cell activation, virus-induced cellular 
dysfunction, immune deficiency, autoimmunity, immunologic memory, and the cellular 
effector mechanisms used to control the viral infections have all been founded based on 
studies performed in LCMV-infected mice (Welsh, 2000). Two Nobel prizes have been 
awarded based on discoveries made with the LCMV system. The first was awarded to 
Burnet based on his theories of immune tolerance (Burnet, 1991). The second was 
awarded to Doherty and Zinkernagel for the discovery MHC restriction, the process by 
which T cells recognized virus-infected target cells through MHC molecules 
(Zinkernagel and Doherty, 1974). 
Although LCMV is a natural pathogen of mice, humans can be infected. LCMV 
infection clinically presents in humans initially as a viremia with fever and myalgia. 
Other symptoms include headache, photophobia, and vomiting. Concurrent with these 
symptoms are leukopenia and thrombocytopenia. This period is followed by the onset of 
the cellular immune response with swelling of the meninges and lymphocyte infiltration 
of the central nervous system (Buchmeier et al., 2001).   
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LCMV was the first arenavirus to be isolated. It has an ambisense RNA genome 
with two gene segments, a long segment (L) and a short segment (S). The genome 
encodes four viral proteins: GP, the viral glycoprotein; NP, the viral nucleoprotein; L, the 
viral polymerase; and z, a RING finger protein that may act as a scaffold for the viral 
glycoprotein (Buchmeier et al., 2001).  The GP protein is a precursor that is cleaved into 
two separate proteins before becoming part of the virion (Wright et al., 1990). The 
interaction between each of these proteins and the cellular immune response has been 
studied. For instance, in C57BL/6 mice, the GP, NP, and L protein epitopes presented by 
MHC class I molecules have been identified, and their subsequent stimulations of CD8 T 
cells have been studied (Whitton et al., 1988; van der Most et al., 1998; Masopust et al., 
2007; Kotturi et al., 2007). The GP and NP epitopes presented by MHC class II 
molecules in C57BL/6 mice and their subsequent stimulation of CD4 T cells have also 
been characterized (Oxenius et al., 1995; Varga and Welsh, 1998a). For B cells, GP is the 
primary target of the neutralizing antibody (Ab) response, although non-neutralizing 
responses against other proteins are also detected (Wright et al., 1989; Battegay et al., 
1993). The details of some of these cellular immune responses will be outlined in later 
sections. 
LCMV may be one of the most useful models of viral infection because it has the 
ability to generate different patterns of disease and different immune responses, 
depending on the route of inoculation, the strain of virus used, the strain of mouse 
infected, and the age of the infected mouse. Three laboratory strains of LCMV were 
originally isolated in the 1930’s: Armstrong, Traub, and WE. Armstrong, named after the 
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person who originally isolated the virus, was isolated from a monkey experiencing severe 
lymphocytic choriomeningitis, hence the virus’ name. Traub, a serologically identical 
strain also named after the investigator who originally isolated it, was found in an 
infected colony of mice at Rockefeller University. WE is a strain isolated from a patient 
“W.E.” who contracted LCMV from the Traub animal colony and subsequently died. 
Some other strains that are used in research were derived from these original three. 
Docile, a highly replicating strain of LCMV isolated from mouse liver was derived from 
WE (Pfau et al., 1982). Clone 13, another highly disseminating strain of LCMV, has a 
broader cellular tropism and better ability to grow in infected cells than its parent strain, 
Armstrong (Ahmed et al., 1984). Each strain and the different immune response 
generated by it has been used to study the various outcomes of viral infection. As an 
example of this, there are differences in hypergammaglobulinemia that occur when 
infecting mice with Armstrong, WE, Docile, and clone 13. These differences and the 
phenomenon of hypergammaglobulinemia will be discussed in section G.  
LCMV infection in mice results in either a long-term persistent infection, an acute 
infection followed by sterilizing immunity, or lethal meningoencephalitis (Welsh, 2000). 
LCMV does not kill the infected host. Instead, the immune response to LCMV causes the 
pathology associated with the virus.  As mentioned above, the route of infection and dose 
of infection can change the outcome of viral pathogenesis and the immune response. If 
the virus is given peripherally at any site, low to moderate doses of virus result in the 
generation of a potent cytotoxic T lymphocyte (CTL) response, which clears the virus, 
and leads to lifelong immunity. However, virus given intra-cranially at these same doses 
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leads to a severe acute meningoencephalitis, with CD8 T cell infiltrates entering the brain 
and meninges. These infiltrates lead to the eventual death of the infected animal.  
Infection with high doses of virus or infection with moderate doses of highly 
disseminating strains of the virus, such as Clone 13 and Docile, results in a completely 
different outcome than acute infection. Here, both peripheral and intracranial (i.c.) 
infections of mice results in persistent viral infections.  A CTL response is generated in 
these mice but rapidly declines, and a phenomenon now known as clonal exhaustion 
occurs which was originally defined as a “high dose immune paralysis”(Hotchin, 1962). 
Clonal exhaustion is a state in which T cells die or become dysfunctional following 
prolonged exposure to antigen (Moskophidis et al., 1993). Several mechanisms have been 
proposed to account for clonal exhaustion, including the loss of functional antigen 
presenting cells (APC) and the absence of CD4 T cell help (Althage et al., 1992; Borrow 
et al., 1991; Borrow et al., 1995; Battegay et al., 1994; Matloubian et al., 1994). Both 
result in less effective CD8 T cell priming and enhancement of clonal exhaustion. Some 
of the receptors and molecular requirements in CD8 T cells for clonal exhaustion are 
beginning to be identified (Barber et al., 2006; Wherry et al., 2007). For instance, the 
over-expression of the CD28 family member PD1 on exhausted CD8 T cells has been 
observed, and blockade of PD1 signaling in CD8 T cells results in the restoration of 
function in clonally exhausted CD8 T cells (Barber et al., 2006).  Others have found that 
the cytokine IL-10 is involved in the exhaustion of CD8 T cells during LCMV clone 13 
infection and that blockade of IL-10 or IL-10R results in the restoration of CD8 T cell 
function and subsequent viral clearance (Brooks et al., 2006; Ejrnaes et al., 2006).  
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The chronic LCMV infection that can occur after high doses of infection or as a 
result of infection with highly disseminating strains of LCMV is due to the clonal 
exhaustion of T cells which prevents the control of virus infection. However, clonal 
exhaustion is not the only means to generate a chronic LCMV infection. Age also plays a 
role in the outcome of LCMV infection. Mice infected with LCMV in utero or less than 
24 hours after birth do not develop a protective T cell response to LCMV. These mice 
enter into a “carrier state” with a persisting life-long viremia.  These observations led to 
the concept of immunological tolerance proposed by Burnet, who stated that the immune 
system will recognize all antigens as self during its development and will not make a 
response to them. Congenitally-infected LCMV carrier mice can, however, generate 
antiviral antibodies that form immune complexes and mediate circulatory system disease 
(Oldstone and Dixon, 1967). Thus, tolerance in congenitally infected LCMV carrier mice 
is restricted to T cells and not B cells. 
The dynamics of the immune response to acute LCMV infection have been well 
characterized. The immune response can be divided into sections according to time after 
infection: the early response, which obviously occurs in the first few days after viral 
infection; the induction phase, which corresponds to the proliferation of lymphocytes in 
response to the virus; the apoptosis phase, which occurs at the height of the immune 
response; the immune silencing phase, which is part of the apoptosis phase and 
corresponds to the reduction in lymphocyte number; and the memory phase which occurs 
at the end immune response after the decline in lymphocyte number. All aspects of the 
mammalian immune system seem to be involved in the clearance of acute LCMV 
 7
infection. Both the innate (Welsh, Jr. and Zinkernagel, 1977; Zhou et al., 2005) and the 
adaptive immune systems are triggered by LCMV infection, and the adaptive immune 
response elicits both humoral (Moskophidis and Lehmann-Grube, 1984) and cell-
mediated responses (Cole et al., 1972).  
The early response to LCMV involves the production of type I interferon (IFN) 
and the induction of NK cells. This phase of the immune response lasts for about four 
days after viral infection. Type I IFN is an antiviral cytokine that is induced to high levels 
following acute infection with LCMV and peaks two days after infection (Merigan et al., 
1977). LCMV infection of mice deficient in type I IFN or type I IFNR signaling generate 
higher LCMV titers. These titers differed among strains of LCMV, suggesting that 
different strains had different susceptibilities to the antiviral effects of type I IFN(Muller 
et al., 1994; van den Broek et al., 1995). Furthermore, strains of LCMV that do not 
normally disseminate into a chronic viral infection can become chronic in mice that lack 
an IFN response. Type I IFNs also activate and induce the proliferation of NK cells 
during this early phase of the immune response to LCMV(Biron et al., 1983; Biron et al., 
1984). However, these NK cells do not seem to play any role in the control of virus 
infection, as mice depleted of NK cells have normal LCMV titers(Bukowski et al., 1983). 
Furthermore, LCMV-infected cells are no more sensitive to NK cell-mediated lysis than 
uninfected cells(Bukowski et al., 1985). In addition to its effect on NK cells, type I IFN is 
also involved in the attrition of memory-phenotype T cells, which occurs around day 3 of 
viral infection (McNally et al., 2001). In an acute infection, mice infected with LCMV 
lose approximately 50% of their memory-phenotype (CD44 high) T cells. This attrition 
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affects CD8 T cells and CD4 T cells, but does not occur in type I IFNR KO mice. This 
loss of memory-phenotype T cells is polyclonal, virus-specific T cells are not spared, and 
it has been hypothesized to be important for the generation of space which may be 
required for the impending immune response (Bahl et al., 2006).  Other studies have also 
indicated that type I IFNs have a direct effect in the clonal expansion of CD4 and CD8 T 
cells during acute LCMV infection (Kolumam et al., 2005; Havenar-Daughton et al., 
2006). Mice deficient in type I IFN R had decreased survival of both CD4 and CD8 T 
cells after LCMV infection. Overall, the signals provided by type I IFNs early after 
LCMV infection help shape the immune response.  
For the clearance of acute LCMV infection, cell-mediated immunity seems to be 
more important than humoral immunity. Mice deficient in B cells clear acute LCMV 
infection, albeit more slowly than mice with an intact B cell compartment(Cerny et al., 
1988; Brundler et al., 1996). However, acutely infected mice deficient in CD8 T cells 
develop a long-term persistent infection (Lehmann-Grube et al., 1993). Although there 
isn’t an absolute requirement for B cells for the elimination of virus, LCMV stimulates B 
cell activation, and humoral immunity is protective against LCMV infection. Transfer of 
a neutralizing monoclonal Ab protects mice after i.c. infection with LCMV even if 
administered up to two days post-infection (Wright and Buchmeier, 1991).  Antibody-
mediated protection, however, may not be completely protective. Studies performed in 
suckling mice where antiviral antibodies were passively transferred to pups by LCMV-
immune mothers showed that only those pups with an intact CD8 T cell compartment 
were protected from neonatal LCMV infection (Baldridge et al., 1997). In this same 
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study, similar results were obtained in adult mice that received neutralizing monoclonal 
antibodies for protection against Clone13. These adult mice were protected from 
persistent clone 13 infections only when CD8 T cells were present.  These results suggest 
that humoral immunity must act in concert with cell-mediated immunity to confer 
protection from LCMV.  
The difference between acute and persistent LCMV infection seems to stem from 
the ability of the host to generate a protective CTL response before the virus grows to 
high levels and induces clonal exhaustion. Antibodies that neutralize infecting particles 
limit early viral spread and allow the cell-mediated response to develop. The cell-
mediated, or T cell response to LCMV develops during the induction phase of the 
infection. Acute LCMV infection induces a massive T cell response(Masopust et al., 
2007). There is an expansion in the number of CD4 and CD8 T cells seen 6 days post-
infection and peaks at 8 to 9 days post-infection. High numbers of LCMV-specific CTL 
can be detected at the peak of the response and CD8 T cells respond more vigorously 
than CD4 T cells in the induction phase (Moskophidis and Lehmann-Grube, 1989; 
McFarland et al., 1992; Varga and Welsh, 1998b). LCMV titers begin to fall at day 5 of 
the acute infection and the virus is basically cleared before the peak in T cell number and 
peak in CTL response. The peak in T cell number also corresponds to peaks in the 
production of IFN-γ, IL-2 production by T cells, and Ab production by B cells(Gessner et 
al., 1990; Kasaian and Biron, 1989; Moskophidis and Lehmann-Grube, 1984).  
Following the induction phase, at 8 to 10 days post-infection, T cells become 
highly sensitive to apoptosis in LCMV-infected mice (Razvi and Welsh, 1993). This 
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apoptosis can be induced through activation-induced cell death (AICD), a phenomenon 
that occurs when IL-2 and antigen receptor stimulation results in the generation of highly 
activated T cells, and when subsequent stimulation through their TCR induces a 
Fas/FasL- or TNF-TNFR-mediated death (Nagata, 1997; Zheng et al., 1995). Although 
AICD is not the mechanism responsible for the silencing of the immune response, it 
seems to correspond with a state of immune deficiency, where the T cells fail to respond 
to other normally mitogenic stimuli. Following the apoptosis phase of the acute LCMV 
response, there is a precipitous decline in lymphocyte number. This phase is known as the 
immune silencing phase. During this phase there is a high level of apoptosis as detected 
by loss of DNA content in cells and TUNEL, an assay that measures DNA fragmentation 
(Razvi et al., 1995; Lohman et al., 1996; Christensen et al., 1996). This apoptosis peaks at 
11 days post-infection and correlates with the loss of T cells and B cells observed during 
this silencing phase at the end of the immune response. Despite this silencing, it is during 
this phase of the immune response that neutralizing antibodies to LCMV can first be 
detected (Battegay et al., 1993).  
Memory, or the ability to respond more rapidly during a secondary response, is 
one of the hallmarks of the mammalian immune system. Memory to LCMV infection has 
been very well characterized. Acute infection with LCMV in normal mice results in the 
development of a long-lasting T cell immunity (Jamieson and Ahmed, 1989). According 
to limiting dilution assays, MHC tetramer staining, ELISPOT analysis, and TCR 
spectratyping, memory CTL frequencies remain high after LCMV infection and stably 
remain high for the lifetime of the animal (Selin et al., 1996; Altman et al., 1996; Murali-
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Krishna et al., 1998; Lin and Welsh, 1998). A similar stability of CD4 T cells has also 
been reported (Varga and Welsh, 1998b). B cell memory has also been characterized 
following acute LCMV infection of mice. Many of these studies used LCMV-specific 
ELISPOT assays where LCMV-specific Ab-producing cells could be enumerated by their 
ability to react with LCMV antigens. These analyses revealed that the bone marrow was 
the major site in which memory B cells resided and, through limiting dilution analysis, 
that the memory B cell precursor frequency is 1 in 20,000 spleen cells(Slifka et al., 1995; 
Slifka and Ahmed, 1996a). Further studies of memory B cell formation following acute 
LCMV infection in mice revealed a critical role for CD40 signaling (Whitmire et al., 
1996). LCMV-infected mice deficient in CD40L had skewed production of Ab isotypes 
compared to LCMV-infected wild type (WT) mice and were completely deficient in 
memory B cell generation. 
This section was meant to provide a broad overview of the LCMV model of virus 
infection. In the following sections I will explore in further detail different aspects of the 
mammalian immune system and describe specific aspects of the immune response to 
LCMV as they relate to my thesis work.  
 
B. T cell subsets. T cells are lymphocytes associated with the adaptive immune 
system and generate cell-mediated immunity. They are categorized by the type of T cell 
receptor (TCR) they express and also by their coreceptors, either CD4 or CD8. TCRs are 
generated by germline gene rearrangements in three gene segments, the variable (V), 
diversity (D), and joining (J) segments.  These VDJ rearrangements occur during T cell 
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development. The TCR exists as a heterodimer with a heavy and a light chain. Heavy 
chains have all three V, D, and J segments whereas light chains have only the V and J 
segments (Fields and Mariuzza, 1996).  There are two types of light chain, alpha and 
gamma, and two types of heavy chain, beta and delta. Gamma-delta T cells are more 
fixed in their TCR gene rearrangement and have been considered to overlap the innate 
and adaptive immune responses (O'Brien et al., 2007; Born et al., 2007). Their 
importance in immune responses has not yet fully been appreciated, but studies in 
vaccinia virus-infected mice showed that gamma-delta T cells can have a significant 
impact on early virus replication, with a corresponding increase in their ability to be 
cytotoxic and in their ability to secrete IFN-γ (Selin et al., 2001). Alpha-beta T cells 
comprise the major population of T cells in the immune system. They recognize antigenic 
peptides that have been processed from larger proteins and presented on major 
histocompatibility complex (MHC) molecules (Zinkernagel and Doherty, 1974). T cells 
with the CD4 co-receptor recognize MHC class II molecules that generally present 
peptides that have been processed from exogenous proteins; that is, proteins from outside 
the cell. CD8 co-receptor-expressing T cells recognize MHC class I molecules that 
generally present peptides from endogenous proteins(Germain, 1994). However, MHC 
class I proteins can present exogenous protein antigens via a process known as cross-
presentation (Bevan, 1976; Rock and Shen, 2005).  MHC class I molecules are presented 
by all somatic cells whereas MHC class II molecules are generally expressed by 
specialized cells of the immune system known as antigen presenting cells (APC) 
(Germain, 1994). Once a T cell recognizes an MHC-peptide complex, the TCRs on the 
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surface of the T cell aggregate. At this point, other molecular interactions between co-
stimulatory molecules occur, and a complex signaling cascade leads to the activation of 
the T cell(Bromley et al., 2001). Both TCR signaling and co-stimulation are required for 
T cell activation(Mondino and Jenkins, 1994). T cell activation is characterized by a set 
of clonal expansions and programmed differentiation where the T cells become effector 
cells. Effector T cells are defined by the cytokines they express and the functions they 
perform.  
CD8 T cells are thought to be involved in what is known as a Th1-type immune 
response. CD8 T cells that become effector cells following activation are generally 
cytotoxic and can produce some Th1-type cytokines, including cytopathic antiviral 
cytokines such as TNF and IFN-γ. Some studies have also suggested that CD8 T cells can 
also express Th2-type cytokines such as IL-4(Mosmann et al., 1995). CD8 T cells are 
also able to produce the cytokine IL-2, which promotes their own survival (Kasaian and 
Biron, 1989; Su et al., 1998). Cytotoxicity by CD8 T cells is mediated by their ability to 
secrete lytic granules that contain granzymes and perforin. Besides granule exocytosis 
and cytokine secretion, CD8 T cells can also lyse target cells by providing ligands for 
death receptors such as Fas. 
CD4 T cells have been categorized into a few major subsets. CD4 T cells are 
often referred to as helper T cells, because the cytokines produced by these T cells help 
direct an immune response toward fighting intracellular or extracellular pathogens, or 
they help prevent tissue damage by suppressing other effector cells in tissues locally. 
CD4 T cells, upon initial encounter with their MHC II-bound antigen, will secrete IL-2, 
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upregulate IL-2R, and divide. These CD4 cells are termed Th0 cells and are cells that can 
differentiate in to any of a number of effector cell types, depending on the cytokines in 
the local environment(Sad and Mosmann, 1994).  
CD4 T cell immune responses vary and have been categorized by the cytokines 
produced during the response. These cytokines play an important role in directing the 
immune response. Th1 and Th2 cytokine responses are probably the best studied 
responses. For many years, all CD4 T cell responses were lumped into either Th1 or 
Th2(Mosmann et al., 1986). However, as more cell types and cytokines were discovered, 
this Th1/Th2 paradigm has shifted to include other Th responses and, as time goes on, 
more responses may be described.  Cytokines produced by Th1 CD4 T cells are IFN-γ, 
TNF, and IL-12(Mosmann et al., 1986; Mosmann and Coffman, 1989). Cytokine receptor 
signaling, particularly IFN-γ receptor, within the CD4 T cell results in the upregulation of 
T-bet, a transcription factor responsible for Th1 development. Cytokines produced by 
Th2 CD4 T cells are IL-4, IL-5, and IL-13(Mosmann et al., 1986; Mosmann and 
Coffman, 1989; Mosmann and Moore, 1991). IL-4 receptor signaling in CD4 T cells 
results in expression of GATA-3, a transcription factor that is responsible for Th2 cell 
development. Interestingly, T-bet and GATA-3 suppress each other’s expression to 
further promote either a Th1 or Th2 response, respectively(Grogan and Locksley, 2002). 
But beside these effects, the cytokines produced by helper CD4 T cells have other 
functions which change the nature of the immune response. For instance, these cytokines 
have a major effect on B cell Ab class switching(Stavnezer, 1996).  
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Other CD4 T cells are known for their ability to suppress or regulate immune 
responses. Regulatory T cells suppress immune responses locally(Bluestone and Abbas, 
2003). They can produce IL-10 and TGF-beta, two cytokines that prevent activation of 
other T cells. Th17 cells are another CD4 T cell subset that has been recently described. 
These cells are characterized by their secretion of IL-17 and are hypothesized to be 
important in the response to extracellular bacteria. This hypothesis is based on the fact 
that secretion of IL-17, IL-22, and IL-23 by Th17 cells recruits neutrophils, promotes 
epithelial cell growth and differentiation, and forms tighter junctions between epithelial 
cells, all which combat bacterial growth. However, these T cells have gained further 
notoriety due to their association with autoimmune or inflammatory conditions, such as 
arthritis, inflammatory bowel disease, psoriasis, and multiple sclerosis (Reiner, 2007). 
Classifying functional subsets of CD4 T cells is becoming more and more difficult as 
CD4 T cell research continues. Cytokines produced by one subset are overlapping with 
the cytokines produced by other subsets. Thus, these categories (Th0, Th1, Th2, T reg, 
and Th17) are used as a guide and will more than likely be refined as more knowledge is 
gained and more subsets are defined. This thesis will describe another function of CD4 T 
cells, cytotoxicity, which had previously only been associated with CD8 T cells in vivo. 
Cytotoxic CD4 T cells add another layer to the complex and varied nature of the CD4 T 
cell immune response.  
 
C. Cytotoxic CD4 T cells. The ability of “killer” CD8+ T cells to lyse virus-
infected cells has been well characterized in vitro and in vivo, but the “helper” CD4+ T 
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cell subset is usually associated with the production of cytokines which provide 
secondary activation or survival signals to APCs, B cells, and CD8 T cells. Some twenty 
years ago, however, CD4 T cells cultivated in vitro were found to have cytolytic potential 
and to lyse targets in an MHC class II-dependent manner (Jacobson et al., 1984; 
Lukacher et al., 1985; Maimone et al., 1986; Hou et al., 1993).  Cytotoxic CD4 T cell 
clones were generated, for example, against influenza virus in the mouse and against 
measles virus, HIV, and Epstein Barr virus in humans.  For a period of time it was 
uncertain whether CD4 T cell cytotoxicity was an artifact of long term in vitro culture 
(Bourgault et al., 1989), but eventually CD4 killer cell activity was found immediately ex 
vivo in cells that had been activated in vivo with keyhole limpet hemocyanin (KLH) (Erb 
et al., 1990) or during HIV infection (Appay et al., 2002).  In contrast to the killing 
mediated by CD8 T cells, however, CD4 T cell-mediated killing had not been 
convincingly shown to occur in vivo.  
In vitro cytotoxicity studies have suggested that CD4 killer T cells, when present, 
may employ similar mediators of cytotoxicity as CD8+ CTL, using TNF-α- (Tite, 1990), 
Fas ligand- (FasL-) (Stalder et al., 1994), and perforin-dependent mechanisms (Williams 
and Engelhard, 1996). Initially it was thought that CD4 T cell killing was mediated 
exclusively by TNF-α or FasL and that perforin was only expressed in CD8 T cells and 
NK cells. However, CD4 T cell clones were eventually shown to sometimes express 
perforin (Williams and Engelhard, 1997), and ex vivo studies from HIV-infected patients 
showed that CD4 T cell-mediated cytotoxicity could occur through a granule exocytosis 
mechanism involving perforin (Appay et al., 2002). Other mechanisms may also be 
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involved.   Two studies reported the involvement of TRAIL in the killing of tumor cells 
by cytotoxic CD4 T cells (Thomas and Hersey, 1998; Kayagaki et al., 1999). It is also 
notable that CD4 killer T cell activity in vitro has been described as a potential function 
of CD4+CD25+ regulatory T cells (Janssens et al., 2003).   
Studies by Lukacher, et al. showed that, after adoptively transferring an influenza-
specific CD4 T cell clone into mice infected with two different strains of influenza virus, 
only the strain of virus recognized by the clone was cleared (Lukacher et al., 1985). This 
was taken as evidence that the antiviral effect of the clone may not involve release of 
soluble mediators but instead was due to exquisite recognition of cells expressing the 
cognate ligand, consistent with a direct cytotoxicity mechanism.  What remains, however, 
is a clear demonstration of antigen-dependent, class II-dependent CD4 T cell-mediated 
killing in vivo. 
 
D. The CD4 T cell response to LCMV As described in section B, LCMV 
infection of mice is a widely-used model system to study viral infections. The LCMV 
infection stimulates strong CD8 and CD4 T cell responses against a number of defined 
MHC class I- (Whitton et al., 1988; van der Most et al., 1998) and MHC class II- 
(Oxenius et al., 1995; Varga and Welsh, 1998a) presented epitopes. CD4 T cell numbers 
increase over the course of an acute LCMV infection. As assessed by intracellular 
cytokine stain, the highest number of epitope-specific cytokine producing  CD4 T cells 
can be detected at Day 9 of acute IP infection of mice with LCMV Armstrong (Varga and 
Welsh, 1998a). LCMV encodes two known MHC class II-restricted epitopes in I-Ab-
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expressing (C57BL/6) mice (Oxenius et al., 1995). The more dominant GP61 response 
can account for around 8 % of the CD4 T cells during an acute infection while the 
subdominant NP309 response can account for around 2% of CD4 T cells during acute 
LCMV infection (Varga and Welsh, 1998a). Acute infection with LCMV Armstrong 
stimulates a strong predominantly Th1 type immune response when administered i.v. or 
i.p., and CD4 T cells can secrete IFN-γ, IL-2, and TNF in response to LCMV peptide 
stimulation (Whitmire et al., 1998; Varga and Welsh, 2000).  
A transgenic CD4 T cell, called SMARTA, that is specific for the LCMV GP61 
peptide in the context of I-Ab has been generated (Oxenius et al., 1998a). These 
SMARTA cells help B cells produce isotype-switched antibodies against LCMV GP. 
They were able to enhance peptide-pulsed target lysis mediated by CD8 T cells in vitro 
and exhibited low levels of MHC class II-restricted cytotoxicity in vitro. SMARTA Tg 
mice, which are deficient in CD8 T cells, could not control acute LCMV infection.  
As described above, LCMV-specific CD4 T cell numbers peak at day 9 post-
infection. This peak is followed by contraction and the emergence of a long-lived CD4 
memory cell pool(Varga and Welsh, 1998b). LCMV memory CD4 T cells rely on IL-15 
and IL-7 for their generation and survival (Purton et al., 2007; Lenz et al., 2004).  More 
recent studies using adoptive transfers of SMARTA transgenic CD4 T cells show that the 
virus-specific CD4 T cell proliferation is nonlinear and CD4 T cells do not start dividing 
until at least two days after viral infection. This is followed by a burst of proliferation and 
an approximately 150-fold expansion. Cytokine expression from these SMARTA CD4 T 
cells changes over the course of infection where early after infection they primarily 
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produce IFN-γ only and at later time points they begin to secrete both TNF and IFN-γ. 
The level of IFN-γ expression by these CD4 T cells also increases over the course of the 
infection, and T cells from later time points required 6-fold less peptide for the 
stimulation of IFN-γ production, suggesting an increase in functional avidity. Using a 
limiting dilution of these SMARTA T cells in adoptive transfers followed by intracellular 
cytokine stain allowed for the enumeration of the naive precursor frequency of a virus-
specific CD4 T cell, which was determined to be 1 in 105 cells (Whitmire et al., 2006).  
CD4 T cells are not necessary for clearance of acute LCMV infection 
(Moskophidis et al., 1987; Ahmed et al., 1988).  However, the absence of CD4 T cells 
resulted in a slight 2-fold reduction in the number of CD8 effector T cells. In contrast, 
CD4 T cells are necessary for viral clearance and for the generation of an effective CD8 
T cell response when higher doses of virus or when more disseminating strains of LCMV 
are used. Battegay et al. showed that infection of CD4-deficient mice with low doses of 
LCMV WE resulted in normal viral clearance and normal CD8 T cell induction. 
However, infection of CD4 knock-out (KO) mice with higher doses of WE or infection 
with the more quickly replicating Docile strain resulted in viral persistence and the 
absence of a protective CTL response(Battegay et al., 1994). Further examination of this 
effect, using CD4 Ab-depleted mice infected with another highly disseminating strain of 
the virus, Clone 13, basically repeated this result(Matloubian et al., 1994).  
A type of clonal exhaustion of CD4 T cells has also been reported following 
chronic LCMV infection. In mice infected with Docile strain of LCMV, CD4 T cells lost 
the ability to stimulate B cell Ab production 6 weeks after infection. In these same 
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studies, CD4 transgenic SMARTA T cells were also analyzed for loss of function after 
adoptive transfer into Docile-infected mice.  SMARTA cells were rendered unresponsive 
in a similar time period and lost their ability to upregulate activation markers and their 
ability to secrete IL-2 (Oxenius et al., 1998b).  Along these lines, CD4 T cells from mice 
challenged with clone 13 had a reduced capacity to secrete IFN-γ in response to peptide 
stimulation as compared to Armstrong-infected mice(Varga and Welsh, 2000). Perforin 
KO mice infected with the Armstrong strain develop a chronic infection resulting from 
the limited ability of perforin KO CD8 T cells to kill virus-infected cells. CD4 T cells in 
these mice also lost their ability to secrete IL-2, but not IFN-γ or TNF(Fuller and Zajac, 
2003).  
CD4 T cells, in addition to their role in sustaining CD8 T cell responses during 
chronic LCMV infection, also seem to play a role in the priming of the CD8 T cell 
response and the formation of good CD8 T cell memory to LCMV. A closer examination 
of the frequency of memory CD8 T cells in CD4-deficient mice following acute LCMV 
infection revealed that these frequencies were much lower than frequencies in WT mice 
(von Herrath et al., 1996). This reduction in frequency was of functional consequence 
when mice were immunized with LCMV-protein-expressing vaccinia virus recombinants 
and subsequently rechallenged i.c. with LCMV. Mice deficient in CD4 T cells were not 
protected from i.c. rechallenge. These results suggested that CD4 T cells were required 
for the generation of a protective CD8 memory response.  A second study looked 
specifically at the ability of these “helpless” CD8 T cells to divide and secrete cytokines 
in response to secondary challenge. LCMV-specific CD8 T cells primed in the absence of 
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CD4 T cells had a reduced ability to expand in response to secondary challenge (Janssen 
et al., 2003).  CD4 T cells were later shown to be required during CD8 T cell priming, at 
the beginning of the response, and were dispensable during the actual memory response. 
This study used an adoptive transfer system where CD8 T cells were taken from CD4-
deficient and sufficient mice that were immunized with LCMV or with LCMV-protein-
expressing vaccinia virus recombinants. These CD8 T cells were transferred into CD4-
deficient hosts and challenged with various LCMV-protein-expressing recombinant 
microorganisms. CD8 T cells from CD4-deficient mice mounted a defective response 
against the challenge with less protection and lower amount of cell expansion (Shedlock 
and Shen, 2003). Further examination of the phenotype of memory CD8 T cells that 
develop in CD4-deficient mice revealed that these CD8 T cells had lower expression of 
CD62L, CD44, CD122 and CD127 than memory T cells generated in WT animals. These 
T cells were also less able to produce IL-2 and TNF upon stimulation.  This phenotype is 
more consistent with the phenotype of a naïve T cell as opposed to a memory-phenotype 
cell (Khanolkar et al., 2004; Fuller et al., 2005).    
 
E. B cells and their activation. B cells are the lymphocytes that comprise the 
humoral immune system. Different B cell subsets have been associated with both 
adaptive and innate immune responses. Unlike the TCR, the B cell receptor (BCR) can be 
secreted, and the secreted BCR, known as antibody (Ab), is the product of a B cell 
response. B cells can be categorized in two distinct manners: first, by their location in 
lymphatic and peripheral tissues and, second, by their antigen receptors and co-receptors.  
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The major B cell compartments in the spleen and lymph nodes are comprised of 
follicular B cells (Martin and Kearney, 2000). These are the conventional B cells that are 
found in all lymphoid organs in an anatomical location known as the B cell or lymphoid 
follicle. These cells align opposite T cells in the lymphoid follicle and their activation is 
T dependent (TD), i.e. their activation is dependent on T cell help. Besides anatomical 
location, they are differentiated from other B cells in lymphatic organs by their high 
expression of CD21, a complement receptor, and of CD23, a low affinity Fc epsilon 
receptor. Activation of these cells results in the formation of a germinal center (GC) 
response which can take several days to occur (MacLennan, 1994a). A second major 
subset of B cells is marginal zone (MZ) B cells (Pillai et al., 2005). These surround the 
lymphoid follicle in the spleen and filter antigens that enter lymphoid tissues via the 
bloodstream, providing a first line of defense against pathogens. These cells are T 
independent (TI), as they do not rely on T cell help for their activation and can be rapidly 
activated during the early immune response. MZ B cells are also differentiated from other 
B cell subsets by lower expression of CD23 and high expression of CD21. Both follicular 
B cells and MZ B cells develop in the bone marrow and migrate as mature cells into the 
spleen and lymph nodes. These cells may have a common precursor. Another major B 
cell population is B1 B cells (Martin and Kearney, 2001). B1 B cells generate TI immune 
responses and are located in the peritoneal and pleural cavities. Their developmental 
origins remain controversial, but B1 B cells are formed during development from fetal 
liver and may have an origin separate from other B cells. What is clear is that B1 BCRs 
are somewhat restricted and recognize conserved epitopes shared between commensal 
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and parasitic organisms in the gut. The conserved nature of their BCR allows B1 B cells 
to give rise to natural or innate Ab. This natural Ab could be considered the very first 
form of humoral immunity to a pathogen because it exists before infections actually 
occur and has been shown to reduce infection levels of viruses and bacteria (Ochsenbein 
et al., 1999a). 
Activation of B cells follows a similar mechanism as T cell activation. B cells 
bind antigens by the BCR. BCR aggregation and crosslinking lead to intracellular 
signaling events that cause a programmed differentiation and clonal expansion of the B 
cell. B cell differentiation can be mediated by CD4 T cell help via costimulation and 
cytokine secretion. The type of help received dictates the type of differentiation that 
occurs, meaning that Th1 T cell help will result in one type of B cell response and Th2 T 
cell helps will result in a different B cell response (Sher and Coffman, 1992). Following 
activation, B cells have two major fates. The first fate allows a B cell to secrete its BCR 
and become a plasma cell. Plasma cells do not divide and are thus at the end stage of their 
differentiation. The second fate is to become a memory B cell. Memory B cells are 
bipotent and upon restimulation can give rise to more memory cells or give rise to newly 
formed plasma cells.  
Part of the B cell differentiation process allows B cells to secrete their BCR. 
Secreted BCR or Ab is a shortened form of the BCR with the transmembrane domain of 
the receptor removed and a secretory signal sequence exposed. Antibody, except when it 
is in the form of secreted dimeric IgA or pentameric IgM, is a homodimeric protein 
connected by disulfide bonds. Each half of the homodimer has a larger heavy chain and a 
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smaller light chain connected to each other by dilsulfide bonds(Alzari et al., 1988). 
Secreted Ab makes its way throughout the body via the circulatory system and 
lymphatics. Upon binding to a pathogen, Ab has several of its own effector functions. 
First, it can bind to and directly inactivate pathogens by blocking entry or attachment 
receptors. Second, it can bind to pathogens and facilitate complement-mediated lysis. 
Third, Ab can lead to sequestration of the pathogen through more efficient opsonization, 
as scavenger cells such as macrophages have receptors that detect Ab. Fourth, other cells 
such as mast cells also have Ab-binding receptors that bind the constant (Fc) region of 
secreted Ab and these Fc receptors, if crosslinked by antigen, can initiate intracellular 
signaling and cellular activation.  
B cells have the capability to undergo two rounds of germline gene 
rearrangement. The first round of rearrangement occurs during development and results 
in the generation of the BCR. The second round occurs following B cell activation and 
results in the class switching of the BCR. A third change in BCR genes can occur via 
point mutations following activation and results in a higher affinity BCR (Li et al., 2004). 
Like the TCR, the BCR subunits also derive from VDJ recombination events that occur 
during development. The heavy and light chains of the Ab must undergo successful VDJ 
recombination for B cell maturation to be completed. The larger heavy chains are 
rearranged first and, if recombination is successful, the heavy chain proteins are paired 
with temporary surrogate light chain proteins while light chain gene rearrangement 
occurs. Two light chain genes are encoded in both mice and humans. Gene rearrangement 
tends to occur in the kappa light chain first and, if this rearrangement is unsuccessful, the 
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lamba light chain gene is rearranged. Successful rearrangement of the light chain and 
subsequent protein expression without self-reactivity signifies the end of naïve B cell 
maturation. These naïve effector B cells are released from the bone marrow to encounter 
antigen (Meffre et al., 2000).  
In addition to heavy and light chains, descriptions of Ab structure can also be 
made by referring to their antigen-binding or variable region and by their constant (Fc) 
regions.  The variable region is formed by germ line gene rearrangements in the V region 
during VDJ recombination.  B cells further differentiate through germline gene 
rearrangements in their Fc region in a process known as class switch recombination, a 
highly regulated process that involves the looping out of gene segments in order to 
produce phenotypically different antibodies (Stavnezer, 1996). This process has been 
extensively studied in mice. B cells develop in the bone marrow expressing only IgM. As 
B cells mature, they express IgD as well, but eventually lose IgD expression following 
activation (Monroe et al., 1983; Monroe and Cambier, 1982). Depending on the type of 
help they receive, B cells then switch to expression of IgG1, IgG2a, IgG2b, IgG3, IgA, or 
IgE isotypes in mice. IgM is the first Ab secreted by B cells and is thus the first Ab 
detected during an immune response. Secreted IgM (sIgM) can exist as a monomer or as 
a pentamer. Many viral infections that induce Th1 immune responses elicit IgG2a and 
IgG3 production by B cells via IFN-γ R signaling. Th2 responses produce IgG1, IgA and 
IgE responses, which depend on signaling from IL-4, TGF-beta, IL-5, and IL-13 
(Stavnezer, 1996).  
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A third change in B cell germline gene sequence occurs during an active immune 
response in distinct lymphoid compartments called germinal centers (GC). Here, B cells 
undergo clonal expansion and somatic hypermutation (SHM), where the BCR V region 
undergoes point mutations in hope of forming higher affinity interactions with antigen, a 
process called affinity maturation (MacLennan, 1994b). Antigen in the GC is presented to 
B cells by follicular dendritic cells (FDC), which can hold antigen in immune complexes 
on their surface for long periods of time. Besides BCR signaling, the GC reaction is 
dependent on T cells which align with B cells within the GC. B cells in the GC reaction 
have phenotypically higher expression of MHC class II and can present antigens taken 
from FDC to CD4 T cells that are induced to provide CD40L.  CD40-CD40L interactions 
are critical for GC reactions, and mice lacking CD40 also lack GC (Van den Eertwegh et 
al., 1993). Other TNF family members such as TACI, BR3, and BCMA and their ligands 
BLyS and APRIL also seem to play some role in the GC reaction (Miller et al., 2006). 
For instance, mice treated with TACI-Fc blocked BLyS stimulation and eliminated the 
GC reaction in the spleen (Yan et al., 2000). B cells in the GC can produce a more potent 
BCR as a result of SHM, but they also can produce a non-functional or a self-reactive 
BCR. Because of the nature of SHM and the selection of B cells based on their ability to 
compete for limiting amounts of antigen, high amounts of apoptosis of lower affinity B 
cells occur in GC reactions (MacLennan, 1994a). The exact molecular mechanism for 
this apoptosis is not fully defined but positive signaling in higher affinity clones seems to 
induce the expression of anti-apoptotic molecules. One of these molecules, BCL-XL, is 
up-regulated in B cells by CD40 stimulation and BCR crosslinking (Choi et al., 1996).  
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Overexpression of BCL-XL reduced apoptosis in GC B cells and lowered the affinity of 
the resulting B cells (Takahashi et al., 1999). Taken together these results suggest that 
low affinity clones with insufficient BCR and CD40 signaling cannot up-regulate BCL-
XL and die in the GC.  The Fas death receptor is up-regulated on all GC B cells, but it 
does not play a role in GC-associated apoptosis (Smith et al., 1995). In addition to clonal 
expansion, SHM, and affinity maturation; GC reactions ultimately induce differentiation 
of B cells into memory or plasma cells. 
Serum antibodies are secreted by activated B cells that have differentiated into 
plasma cells. Some plasma cells are short-lived and contribute to clearance of the primary 
viral infection, whereas others are long-lived and can produce neutralizing Ab for several 
months or years following the primary infection (Manz et al., 1997; Slifka et al., 1998). 
One would think that, except in the case of persistent infection or secondary challenge, 
serum Ab would disappear after a few months, but this is not the case, as titers can be 
maintained throughout a lifetime without obvious additional antigen stimulation (Manz et 
al., 1998). Several mechanisms have been proposed to explain this observation. One is 
that some plasma cells are long living and sufficient to maintain serum Ab (Slifka et al., 
1998). Another model suggests that persisting or cross-reactive antigen induces memory 
cells to divide and differentiate into plasma cells throughout an organism’s lifetime 
(Ochsenbein et al., 2000; Traggiai et al., 2003). I will propose an additional model based 
on the observations of hypergammaglobulinemia associated with virus infections and on 
the work presented in this thesis that describes a virus-induced polyclonal B cell 
activation. 
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F. The B cell response to LCMV. The humoral immune response to LCMV is 
delayed in comparison to the cell-mediated response. Antibody responses are generated 
against all viral proteins but not all of these Ab are neutralizing(Battegay et al., 1993). 
Antibodies that react with LCMV can be detected by day 7 following infection 
(Moskophidis and Lehmann-Grube, 1984; Battegay et al., 1993). However, neutralizing 
Ab to acute LCMV infection cannot be detected until 30 days following initial exposure 
to the virus, long after virus has been cleared from the host (Battegay et al., 1993; Recher 
et al., 2004). The non-neutralizing Ab can bind to antigenic determinants on both LCMV 
NP and GP whereas neutralizing Ab is specifically reactive with LCMV GP1 (Battegay 
et al., 1993; Bruns et al., 1983; Wright et al., 1989). LCMV neutralizing Ab prevents 
binding of GP1 with its receptor, alpha dystroglycan(Cao et al., 1998). LCMV stimulates 
an IgM response followed by a class-switched IgG response, where IgG1, IgG2a, IgG2b 
and IgG3 reactive with LCMV are generated(Slifka et al., 1995). Secretory IgD, which is 
considered an oddity for most B cell responses, can also be detected as a result of acute 
LCMV infection(Moskophidis et al., 1997). IgG2a is the predominant Ab produced that 
binds LCMV (Whitmire et al., 1996). CD4 T cell help is required for optimal class-
switched B cell responses to LCMV, and this help seems to come from CD4 T cell 
provision of CD40L. CD40LKO mice mount a reduced IgG response to LCMV with a 
complete absence of IgG1 production (Whitmire et al., 1996). Following reinfection with 
LCMV, memory B cells respond rapidly, and LCMV-specific ASC numbers in the spleen 
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peak at day 5 post-infection. These numbers are then dramatically reduced at day 15 in 
the spleen, corresponding to an increase in ASC number in the BM (Slifka et al., 1995).  
 Neutralizing antibodies have been shown to be important in protection against 
reinfection with LCMV and for protection against lethal LCMV infection, but the 
humoral response to acute LCMV is not required for viral clearance, as seen in B cell-
deficient mice (Thomsen and Marker, 1988; Wright and Buchmeier, 1991) (Cerny et al., 
1988; Cerny et al., 1986). Other studies have shown that mice deficient in B cells 
succumb to i.c. inoculation of LCMV Armstrong with the same kinetics as WT mice, 
suggesting that LCMV-induced immune pathology is not altered by B cells (Planz et al., 
1997). However, mice deficient in B cells can develop a persistent LCMV infection more 
readily than WT mice. CTL memory in B cell KO mice is not well maintained and mice 
can develop persistent infections. Experiments performed in genetically B cell-deficient 
mice infected with the LCMV Traub strain i.v. showed that B cell KO mice had a delayed 
but detectable CTL response early after viral infection. In these mice, virus levels 
dropped but were still detectable early after infection. Eventually, however, viral titers 
rose to high levels in the blood and lung 30 days post-infection, resulting in persistent 
infection in the B cell KO mice, but not WT mice. Corresponding to this recrudescence 
of virus was the loss of the CTL response (Thomsen et al., 1996). In agreement with this 
study, these same genetically B cell-deficient mice, when infected with high dose 
LCMV-WE or the rapidly growing strain Docile, developed a persistent infection and lost 
virus-specific CTL. However, if B cell-deficient mice were first primed with low dose 
LCMV-WE they were able to efficiently clear a high dose rechallenge, suggesting that 
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memory CTL can actually be generated and maintained in the absence of B cells during a 
low dose infection, but these CTL are lost if higher doses of virus are present(Brundler et 
al., 1996). B cells may function as APC for CD4 T cells which are also required for the 
maintenance of an effective CTL response. However, the defective CTL response and 
persistent viral infection in B cell KO mice may be the result of a reported reduction in 
the overall CTL number in LCMV-infected B cell KO mice at the peak of the response 
and an improper rescue of memory CTL during the attrition phase of the immune 
response to acute LCMV infection in B cell KO mice (Asano and Ahmed, 1996). Thus, in 
the absence of B cells, the balance between the number of CTL and viral replication may 
be tipped in favor of virus replication and CTL become susceptible to clonal exhaustion. 
Consistent with this hypothesis, other studies on the exhaustion of CD8 T cells following 
adoptive transfer into congenital LCMV carrier mice have shown that pre-activated B 
cells can prevent CD8 T cell exhaustion in these mice and that the effect is most likely 
due to the production of neutralizing Ab, which lowers viral burden (Planz et al., 1997; 
Hunziker et al., 2002). It still remains to be clarified exactly what B cells provide in these 
situations that prevents clonal exhaustion.   
LCMV-specific plasma B cells home to the bone marrow, where they are 
maintained (Slifka et al., 1995). Using limiting dilution analysis, the precursor frequency 
of memory B cells in the spleen was determined to be about 1 in 20,000 splenocytes or 
about 1 in 10,000 B cells (Slifka and Ahmed, 1996a). LCMV memory B cells also reside 
in the bone marrow. This was concluded based on a virus-specific enzyme-linked 
immunospot assay (ELISPOT) to determine precursor frequency, which relies on a 
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limiting dilution analysis of ASC and is predicated on the fact that LCMV memory B 
cells will become Ab-secreting plasma cells after in vitro stimulation. Thus, the Ab-
secreting daughter cells of LCMV-specific memory B cells are actually counted in the 
assay. The phenotype of mouse memory B cells is not identifiable by flow cytommetry, 
and there is not much known about the LCMV memory B cell response. There are no 
means to detect LCMV-specific B cells, and there have been no reports of fluorescently 
labeled virions or virus proteins that could be used to “see” virus-specific B cells. Much 
of what is known about the B cell response to LCMV was discovered by examining 
LCMV-specific Ab with enzyme-linked immunosorbant assays (ELISA), ELISPOT, or 
virus neutralization assays.  However, some recent reports on the B cell response to 
LCMV have used B cell hybridomas to generate LCMV-specific B cell transgenic mice. 
Two transgenic mice with B cells that generate neutralizing IgM antibodies 
against LCMV have been created. These mice were created by targeting the IgM heavy 
chain and kappa light chain genes from the LCMV-specific KL25 B cell hybridoma into 
mice. The resulting mice are called H25, which expresses the heavy chain of the KL25 
IgM only, and HL25, which expresses both the heavy and light chains of the KL25 IgM. 
H25 mice mounted a neutralizing Ab response 8 days after acute LCMV infection, and 
this improved the host’s ability to clear the virus. HL25 mice spontaneously produced 
neutralizing IgM that protected mice immediately after LCMV infection but did not 
generate a CTL response, presumably because viral antigen was cleared before it could 
be processed by APC (Seiler et al., 1998). HL25 B cell transgenic mice were also used to 
assay B cell tolerance induction in congenitally-infected LCMV carrier mice by crossing 
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the HL25 transgenic mice with congenitally-infected mice. Virus isolated from the 
resulting HL25 transgenic LCMV carrier mice was a neutralization resistant variant of 
LCMV, and no evidence of B cell tolerance was observed in these mice (Seiler et al., 
1999). This study highlights how difficult it is to generate B cell tolerance to virus 
infections, because the transgenic carrier mice did not delete what should be considered a 
“self reactive” anti-LCMV transgenic B cell response. Another LCMV-specific B cell 
transgenic mouse was generated by targeting only the variable and diversity regions of 
the heavy chain genes from the KL25 B cell hybridoma into mice(Hangartner et al., 
2003). The resulting mice, called TgH(KL25), have B cells that can generate a more 
dynamic neutralizing Ab response against LCMV and class switch from IgM to IgG. 
These mice rapidly generate neutralizing Ab responses after the third day of infection. 
TgH(K25) mice had reduced viral loads and generated a CTL response during acute 
LCMV infection. Additionally, these mice avoided clonal exhaustion when challenged 
with a high dose of virus due to Ab-mediated reduction in viral load. Generation of a TD 
IgG response was observed in TgH(K25) mice but interestingly, TgH(25) transgenic mice 
also generated a TI IgM response to LCMV when CD4 T cells were absent(Hangartner et 
al., 2003).  This was an unexpected result because previous investigations of anti-LCMV 
responses performed in CD4-deficient mice did not detect a TI neutralizing Ab response 
(Ahmed et al., 1988). 
 
G. Hypergammaglobulinemia and virus-induced polyclonal activation of B 
cells.  The adaptive immune system is designed to mount a rapid antigen-specific 
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response to pathogens by way of clonal expansions of T and B cells bearing discrete 
antigen-specific receptors.  For several decades, however, it has been noted that a number 
of human viral infections, including those caused by Epstein Barr virus (EBV), 
cytomegalovirus (CMV), human immunodeficiency virus (HIV), and hepatitis C virus 
(HCV), seem to elicit Ab responses to non-viral antigens, including self-antigen(Hu et al., 
1986; Burgio and Monafo, 1983; Martinez-Maza et al., 1987; Hutt-Fletcher et al., 1983; 
Rosa et al., 2005). In some cases, there is a demonstrable hypergammaglobulinemia and a 
presumed but mostly undefined polyclonal activation of B cells. During the course of my 
thesis work, autoantibody production associated with this phenomenon was observed in 
mice infected with LCMV, vaccinia virus, and vesicular stomatitis virus (VSV), where 
autoantibody production mirrored some of the autoantibody specificities detected in 
human infections (Hunziker et al., 2003; Ludewig et al., 2004). This presumed polyclonal 
B cell activation associated with virus infection is of great medical interest because it 
may be involved in the initiation of autoimmunity or contribute to the long-term 
maintenance of B cell memory.  
Clonal B cell activation requires a signal though a specific antigen receptor (BCR) 
and costimulation by a secondary receptor.  These two signals result in the specific 
activation of one B cell. Polyclonal B cell activation is not specific and can occur through 
many proposed mechanisms, including: signals generated by innate pattern recognition 
molecules, such as Toll-like receptors (TLR); mitogenic cytokine signals, such as those 
provided by IL-4; non-specific T cell help, such as the provision of costimulation ligands; 
cell transformation, which occurs following EBV infection; and superantigen signals, that 
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occur following binding of staphylococcal protein A to the BCR. All of these can lead to 
the polyclonal activation of B cells. It is not clear whether the two signal model of 
activation is required for polyclonal B cell activation, but constant with all of these 
polyclonal activators is global B cell activation and the absence of specific BCR 
triggering, meaning that both naïve- and memory-phenotype cells could potentially be 
activated.  
Polyclonal activation of  B cells without BCR triggering has been reported in 
vitro with human memory B cells stimulated by TLR agonists or with CD4 T cell 
help(Bernasconi et al., 2002). In these studies, B cells were isolated from blood and 
separated based on CD27 expression into naïve-phenotype (CD27-) and memory-
phenotype (CD27+) B cells. The memory-phenotype B cells were also separated into IgG 
and IgM receptor-expressing cells. CD27 expression on human B cells has been shown to 
correlate with previous antigen encounter and subsequent somatic mutation (Klein et al., 
1998). Once separated, the B cells were stimulated with either TLR agonists or by 
alloreactive T cells that could provide CD40L and cytokines to the B cells subsets. These 
stimulations can be called polyclonal stimuli because they are not specific for any one B 
cell.  Despite a presumed requirement for BCR triggering, the memory B cells responded 
to the TLR stimulation and to the surrogate T cell help without Ab receptor triggering. 
The B cells divided, changed their surface phenotype, and secreted Ab in response to the 
polyclonal stimuli. Of note, IgG-expressing B cells were more responsive to these stimuli 
than IgM-expressing cells.  These findings led the investigators to believe that there were 
conditions under which B cells could become activated in the absence of BCR 
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stimulation. They proposed that polyclonal activation of memory B cells may account for 
the maintenance of memory B cells and the maintenance of serum Ab levels throughout 
an organism’s lifetime (Bernasconi et al., 2002; Traggiai et al., 2003).  
The biological significance of polyclonal B cell activation can be speculated to be 
beneficial or detrimental. The above study illustrates that the outcome of polyclonal B 
cell activation can be beneficial and potentially lead to sustained B cell memory. 
However, because polyclonal B cell activation is non-specific, auto-reactive B cell clones 
may also be maintained by polyclonal activation, a potentially harmful effect. However, 
B cell maintenance may not be the only biological significance for polyclonal B cell 
activation.  
There are many ways to polyclonally activate B cells, and many infectious agents 
have been presumed to induce polyclonal B cell activation because these infections have 
been associated with the induction of hypergammaglobulinemia. 
Hypergammaglobulinemia may be caused by polyclonal B cell activation but, for the 
most part, these B cells have not been identified. Some have proposed that this 
hypergammaglobulinemia is meant to increase the levels of natural Ab that can eliminate 
some of the early spread of infectious agents (Ochsenbein et al., 1999a). Natural 
antibodies are germ-line-encoded antigen recognition molecules that bind conserved 
patterns in many pathogens. Hypergammaglobulinemia induced by polyclonal B cell 
activation, because it is non-specific, could lead to increased natural Ab production. It has 
also been proposed that polyclonal activation, because it activates all B cells, may induce 
the production of some pathogen-specific antibodies, although at low frequency. 
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However, these low frequencies may be relevant early in infection when the infectious 
particles are low in number(Ochsenbein et al., 1999b). Elevations in natural Ab and 
elevations in pathogen-specific antibodies are further examples of how polyclonal B cell 
activation could be beneficial, but because many of the antibodies produced by  
polyclonal B cell activation would not be pathogen-specific, some infectious agents may 
have evolved to induce polyclonal B cell activation as a means to dilute the specific Ab 
response, thus allowing more time for pathogen growth in the host (Hunziker et al., 2003; 
Minoprio et al., 1988).  
Several microorganisms, including viruses, bacteria, and protozoans can induce 
hypergammaglobulinemia. The mechanisms used to induce hypergammaglobulinemia are 
shared between different classes of microorganism. For instance, different pattern 
recognition molecules can be triggered by viruses, bacteria, and protozoans. Due to the 
complex nature of polyclonal B cell activation and the many pathogens that induce 
hypergammaglobulinemia, for the remainder of this section, I will focus primarily on 
virus-induced hypergammaglobulinemia and describe virus infections where, for the most 
part, polyclonal B cell activation has been presumed, but not clearly documented. 
Some viruses such as EBV directly infect B cells. In these cases, activation of the 
infected B cell may be due to mitogenic signals generated during the infection process or 
due to the transformation of B cells by the virus. EBV infection can transform B cells and 
can cause B cell lymphomas(Kuppers, 2003). EBV does not seem to selectively infect 
certain B cells, and this transformation can thus be considered a type of polyclonal 
activation. Transformation may not be the only way EBV can polyclonally activate 
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infected B cells. In vitro infection of B cells with the P3HR-1 strain of EBV, a strain that 
cannot transform B cells, showed that these infected B cells would readily down-regulate 
IgD and elevate thymidine incorporation more than uninfected B cells if they were 
exposed to supernatants from in vitro cultures of activated T cells (Hu et al., 1986). 
Division, as measured by thymidine incorporation, and down-regulation of IgD are 
consistent with events that would occur with other polyclonal activators. EBV also 
encodes a protein LMP1 which acts as a constitutively active CD40 signal in infected B 
cells and causes those B cells to proliferate (Kilger et al., 1998). Although it has not 
formally been tested, LMP1 may have caused the polyclonal B cell activation induced by 
the P3HR-1 EBV strain. Not only does direct EBV infection cause polyclonal B cell 
division but EBV infection of human lymphocytes leads to polyclonal Ab production 
(Rosen et al., 1977). This polyclonal Ab production includes the production of 
“heterophile antibody” which reacts with the red blood cells of other species(Paul and 
Bunnell, 1974; Duverlie et al., 1989). The production and detection of this heterophile Ab 
was exploited by clinicians as a means to diagnose infection with EBV in a test known as 
a Paul-Bunnell antibody test (Burgio and Monafo, 1983). This test, or variations of it, is 
still used to diagnose EBV infection in humans. EBV is one of the only human viral 
infections where polyclonal B cell activation and hypergammaglobulinemia are both 
described. For other infections, hypergammaglobulinemia is observed, but polyclonal B 
cell activation per se has not been formally described.   
Other viruses do not readily infect B cells, yet still evoke 
hypergammaglobulinemia in infected patients. Patients with CMV mononucleosis present 
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with unusually high numbers of Ab-secreting lymphocytes as well as increases in Ab 
irrelevant to viral antigens. Peripheral leukocytes from CMV seronegative donors 
produced Ab when exposed to both live and UV-irradiated CMV in the relatively short in 
vitro culture where the generation of a specific antiviral response is unlikely and, in this 
case, viral infection of B cells was not driving Ab production (Hutt-Fletcher et al., 1983).  
The specific mechanism by which CMV activates human B cells remains unclear.  
HCV is another virus that seems to induce polyclonal B cell activation in infected 
patients. For HCV, hypergammaglobulinemia is known as cryoglobulinemia. 
Cryoglobulinemia is a high frequency of serum Ab that undergo a reversible precipitation 
when exposed to cold temperatures. The resulting cryoglobulinemia seems to stem from 
increased IgG and IgM levels that are generated by a naïve-phenotype (CD27-) 
population of B cells (Racanelli et al., 2006). HCV interaction with CD81 receptor on B 
cells might be the trigger that induces cryoglobulinemia. In vitro studies show that 
stimulation of CD81 on naïve-phenotype B cells leads to their activation (Rosa et al., 
2005). The HCV protein E2 binds CD81 and uses it as an entry receptor. Based on these 
observations, it was proposed that HCV E2 protein binding of CD81 could activate B 
cells and cause the cryglobulinemia. The nonspecific nature of the cryoglobilinema was 
speculated to be due to that fact that naïve-phenotype B cells express more CD81 than 
previously-activated B cells. CD81 stimulation of naïve B cells by HCV E2 would 
therefore effect non-HCV-specific B cells more than the activated HCV-specific B cells 
and generate the non-specific cryoglobulinemia.  
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Another example of human viral infection that is associated with 
hypergammaglobulinemia is HIV. HIV may employ multiple mechanisms to induce 
polyclonal B cell activation. Some of the earliest reports in AIDS research showed that 
patients infected with HIV had a hypergammaglobulinemia and presumed polyclonal B 
cell activation (Lane et al., 1983). Based on these clinical observations, researchers tested 
the ability of HIV to stimulate B cells in vitro, similar to the studies performed with 
CMV. Peripheral blood B cells exposed to the HIV virus in vitro became activated and 
divided, as seen by Ab secretion and thymidine incorporation(Schnittman et al., 1986). 
Others later found that B cells isolated from the peripheral blood of HIV positive 
individuals were more likely to display activation markers and had elevated levels of 
spontaneous Ab-producing cells than uninfected individuals (Martinez-Maza et al., 
1987). These results showed that B cell exposure to HIV could result in polyclonal B cell 
activation in vitro but the mechanism of HIV-induced polyclonal B cell activation both in 
vitro and in vivo remained undefined.   
HIV-associated hypergammaglobulinemia is seen throughout the course of an 
HIV infection from initial virus exposure to the development of AIDS.  Early in 
infection, hypergammaglobulinemia is hypothesized to be T cell-dependent because some 
studies found that HIV-infected cultures containing CD4 T cell clones could induce a 
high frequency of a polyclonal population of B cells to secrete Ab in vitro (Macchia et 
al., 1993; Chirmule et al., 1993). Several interactions were identified that govern this T 
cell-dependent antibody secretion. Some claimed that TNF expression on infected CD4 T 
cells was required. Antibody blockade of either TNF or TNF receptor by mAb treatment 
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eliminated Ab production by activated B cells (Macchia et al., 1993). In this study, 
CD40L expression was not required on T cells. Other groups performed trans-well assays 
using both whole virus or the HIV protein gp160 and in these studies it was found that 
Ab secretion in vitro was dependent on three things: direct contact between T and B cells, 
the expression of CD40L on T cells, and IL-6 receptor stimulation (Chirmule et al., 
1993). The discrepancies in these results remain unresolved and with the exception of 
CD40L it is not clear that either study ruled out possible overlapping roles of TNF and 
IL-6. These discrepancies may also be due to the fact that the experiments were done in 
vitro with T cell lines grown under different conditions. Nevertheless, CD4 T cells were 
found to be critical to induce this in vitro Ab secretion by HIV in both studies.   
As mentioned above, hypergammaglobulinemia is seen both early and late during 
HIV infection, when CD4 T cells are nearly absent. The hypergammaglobulinemia seen 
in AIDS patients who lack CD4 T cells may be driven by other mechanisms. Cytokine 
involvement, specifically from IL-15, has been associated with AIDS-related 
hypergammaglobulinemia. Clinically, AIDS patients experiencing 
hypergammaglobulinemia had elevated levels IL-15 (Kacani et al., 1997). It was 
hypothesized that the elevated levels of IL-15 may have some involvement in late-stage 
HIV-induced hypergammaglobulinemia. Consistent with this hypothesis, exposure to 
heat-inactivated HIV along with IL-15 resulted in a dose-dependent increase of 
thymidine incorporation in human peripheral blood B cells in vitro (Kacani et al., 1999). 
Based on these results, the hypergammaglobulinemia seen during the late stages of HIV 
infection may be due to IL-15 stimulation of B cells. More recently, gp120, a protein 
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from the envelope of HIV, was also shown to activate naïve B cells through a mannose 
binding receptor. Stimulation of this receptor induced DNA synthesis and Ab production 
by these B cells (He et al., 2006). This mannose binding receptor-mediated polyclonal 
activation may play a role in both the early HIV- and late AIDS-associated 
hypergammaglobulinemia.  
In addition to clinical observations of hypergammaglobulinemia, several studies 
have noted this phenomenon in mouse models of viral infection. Similar to the 
observations made in humans, hypergammaglobulinemia is described but polyclonal B 
cell activation in vivo remains undefined except in cases where B cells are directly 
infected by the virus.  Infection of mice with lactate dehydrogenase-elevating virus 
(LDV) is one example of murine infection that induces hypergammaglobulinemia. 
Expression of IgG2 isotypes were specifically elevated in LDV-infected mice 
experiencing hypergammaglobulinemia (Li et al., 1990). This Ab response could occur in 
the absence of a virus-specific response (Rowland et al., 1994). It was not strain 
dependent and even occurred in immunocompromised nude mice (Coutelier et al., 1990). 
However, in contrast to the results in nude mice, LDV-induced hypergammaglobulinemia 
was found to be partially dependent on CD4 T cells as seen by in vivo depletion studies, 
where depletion of CD4 T cells in LDV-infected mice greatly reduced the levels of IgG 
production (Li et al., 1990). Expression of carbohydrates on the surface of the LDV 
envelope protein seemed to be the viral determinant that induced 
hypergammaglobulinemia (Plagemann et al., 2000). Viruses that lack two of these 
glycans had greatly reduced hypergammaglobulinemia. In some strains of mice, IL-6 was 
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found to be important for LDV-induced hypergammaglobulinemia. Mice lacking IL-6 
had reduced hypergammaglobulinemia compared to WT mice following infection with 
LDV, but IL-6 KO mice bred onto the common C57BL/6 strain did not have reduced 
levels of hypergammaglobulinemia (Markine-Goriaynoff et al., 2001). Thus, the 
dependence on IL-6 for LDV-induced hypergammaglobulinemia varied, based on the 
genetic background of the mouse.  
LDV is just one of many viruses that cause hypergammaglobulinemia in mice. 
Early studies included infection with LDV, LCMV, adenovirus, murine coronavirus 
MHV-A59, and Sendai virus (Coutelier et al., 1988). Murine cytomegalovirus (MCMV) 
and murine gammaherpesvirus 68 (MHV68), two herpesviruses respectively used as 
mouse models of CMV and EBV in humans, were later also identified as viruses that 
could induce a hypergammaglobulinemia in mice (Price et al., 1993; Stevenson and 
Doherty, 1998). With the exception of Sendai virus, which has not yet been tested, all of 
these infections in mice require CD4 T cells to induce hypergammaglobulinemia 
(Coutelier et al., 1994; Stevenson and Doherty, 1999; Coutelier et al., 1990; Price et al., 
1993; Lardans et al., 1996). In each of these cases depletion of CD4 T cells resulted in a 
dramatic reduction in hypergammaglobulinemia. With the exception MHV68, where B 
cells can be directly activated by a viral protein or perhaps by viral infection, the specific 
mechanisms driving hypergammaglobulinemia in these other mouse models of infection 
remained unknown. Polyclonal B cell activation is presumed to be the mechanism, but, 
again, it has not been clearly demonstrated. 
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Several studies were undertaken using the LCMV model of mouse infection that 
led to the presentation of an entirely different mechanism to explain the induction of 
hypergammaglobulinemia. During the course of my thesis work, Hunziker et al. 
performed seminal studies in which they investigated conditions under which LCMV 
could induce hypergammaglobulinemia and the effects hypergammaglobulinemia had on 
autoantibody induction (Hunziker et al., 2003). Also concurrent with my thesis, Recher et 
al. investgated the effects of hypergammaglobulinemia on the generation of virus-specific 
neutralizing Ab (Recher et al., 2004). Initial experiments were performed by Hunziker et 
al. using different strains of LCMV: Armstrong, Docile, Clone 13, and WE. While all 
strains induced hypergammaglobulinemia at the same dose of infection in the same strain 
of mice, only the less virulent Armstrong strain and the more virulent LCMV-WE strain 
were cleared from infected mice and did not establish a persistent infection. Of the two 
strains, LCMV-WE generated a longer lasting and greater level of 
hypergammaglobulinemia and grew to higher titers in mice than Armstrong. This 
correlation between viral load and hypergammaglobulinemia was noted, and was 
confirmed by generating reassorted viruses, where the polymerase that controls viral 
replication for LCMV was swapped between the two viruses. In this case, LCMV 
Armstong with the WE viral replication gene induced the same level of 
hypergammaglobulinemia and had the same viral load as the original LCMV-WE, and 
LCMV-WE with the Armstrong viral replication gene resembled the 
hypergammaglobulinemia and viral loads generated by the original Armstrong strain. 
LCMV-WE was used in subsequent experiments because it induced higher levels 
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hypergammaglobulinemia than Armstrong, and Hunziker et al. proposed that use of a 
persistent strain like Docile or Clone 13 may complicate experimental results due to the 
potential effects of clonal exhaustion and chronic stimulation of LCMV-specific B cells 
in persistently infected mice.   
Hunziker et al. next infected several inbred mouse strains as well as several 
strains of knock out mice with LCMV-WE to determine if there was anything specifically 
required from virus-infected hosts that might induce hypergammaglobulinemia. Mice 
lacking cytokine responses, such as type I IFN R, IL-6, and IL-12 as well as mice 
defective in Th skewing cytokines, such as IL-4(Th2-inducing) and IFN-γ (Th1-inducing) 
all experienced hypergammaglobulinemia following LCMV-WE infection. These results 
indicated that these cytokines were not required for LCMV- induced 
hypergammaglobulinemia. Furthermore, every strain of mouse infected experienced 
hypergammaglobulinemia, suggesting that the phenomenon was not laboratory strain-
specific.  
Previous studies on the hypergammaglobulinemia associated with adenovirus 
infection found that up to 90% of the Ab produced did not bind viral particles (Coutelier 
et al., 1988). To confirm that non-virus-specific antibodies could also be produced during 
the LCMV-induced hypergammaglobulinemia, Hunziker et al showed that 
quasimonoclonal mice, in which 80% of the B cells were all of the same known 
specificity and not LCMV-specific, had increased levels of the quasimonoclonal Ab 
species after infection with LCMV-WE. Additionally, WT mice infected with LCMV-
WE developed antibodies that reacted with other viruses such as VSV and influenza and 
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some mice developed self-reactive antibodies that bound thyroglobin, DNA, and insulin. 
These additional results lend evidence to the potential biological significance of 
polyclonal activation described earlier and show that non-virus-specific antibodies can be 
produced as a result of LCMV-induced hypergammaglobulinemia.  
CD4 T cells were found to be important for hypergammaglobulinemia induced by 
other viruses. Hunziker et al found that CD4 T cells were also required for LCMV-
induced hypergammaglobulinemia because CD4 T cell KO mice did not experience 
hypergammaglobulinemia following LCMV-WE infection. However, the role of CD4 T 
cells was refined in these studies using mice deficient in CD40L, a key costimulatory 
molecule for CD40 on B cells. CD40 is required for proper B cell activation, including 
GC and memory formation(Foy et al., 1994). These CD40L KO mice also did not 
experience hypergammaglobulinemia following LCMV-WE infection. Hunziker et al. 
next asked if any CD4 T cell could induce hypergammaglobulinemia or if virus-specific 
CD4 T cells were required. To test this, they transferred virus-specific transgenic 
SMARTA CD4 T cells into congenital LCMV carrier mice and into mice that 
ubiquitously express LCMV GP and assayed for hypergammaglobulinemia. In both 
cases, the SMARTA T cell transfer resulted in hypergammaglobulinemia. However, 
when a non-LCMV-specific transgenic T cells was transferred, no Ab production was 
seen. These results refined the CD4 T cell requirement that had been previously proposed 
by others. For LCMV-induced hypergammaglobulinemia, CD40L and virus-specific CD4 
T cells are required.   
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Thus far, Hunziker et al identified CD40L and virus-specific CD4 T cells as 
requirements for LCMV-induced hypergammaglobulinemia and noted a correlation 
between high viral loads and hypergammglobulinemia. Non-virus-specific Ab production 
had also been demonstrated. These observations, when taken together, led Hunziker et al. 
to propose that in situations where there is high antigen load, non-virus-specific B cells 
must be able to present viral antigens to virus-specific CD4 T cells which induces Ab 
production and hypergammaglobulinemia. To show that non-LCMV-specific B cells had 
the ability to present LCMV antigens, they isolated B cells from the LCMV-WE-infected 
quasimonoclonal mice and exposed them to a T cell hybridoma that was specific for 
LCMV in vitro. Quasimonoclonal B cells from LCMV-WE-infected mice but not from 
uninfected mice stimulated the T cell hybridoma. These results led Hunziker et al. to 
conclude that non-LCMV-specific B cells could present viral antigens to CD4 T cells.  
If the BCR is not used to internalize viral antigens, B cells may use complement 
or Fc receptors to endocytose virus or viral antigens. Alternatively, viral antigen may be 
internalized by general pinocytosis. To investigate these possibilities, mice missing C3 (a 
ligand for CD23), the complement receptor CR2, CD19, Fc gamma receptor, and IgM 
(mice that do not express IgM but do express IgD and can switch to IgG) were infected 
with LCMV-WE by Hunziker et al. and assayed for hypergammaglobulinemia. In every 
case, the LCMV-WE-infected knock out mice still experienced 
hypergammaglobulinemia. These results suggested that none of the traditional antigen 
uptake mechanisms used by B cells could account for how B cells presented antigen to T 
cells. Hunziker et al. concluded from these studies that generalized pinocytosis was most 
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likely the entry route for viral antigen. The final conclusions made by Hunziker et al were 
that LCMV-induced hypergammaglobulinemia was the result of high in vivo antigen 
loads and these high viral loads allowed non-LCMV-specific B cells to present LCMV 
antigens to LCMV-specific CD4 T cells that activated those B cells by a CD40L-
dependent mechanism.  
Another study of LCMV-induced hypergammaglobulinemia, also performed 
concurrent with my thesis work, investigated the effect of hypergammaglobulinemia on 
the generation of a virus-specific neutralizing Ab response (Recher et al., 2004). Previous 
observations had been made that LCMV-infected mice lacking CD8 T cells had reduced 
hypergammaglobulinemia and an earlier onset of virus-specific neutralizing Ab (Battegay 
et al., 1993). The CD4 T cell requirement for hypergammaglobulinemia had already been 
established by Hunziker et al. and CD8 T cells were not required in those studies 
(Hunziker et al., 2003). It was reasoned that, under normal circumstances, CD8 T cells 
may help control viral titers and prevent CD4 T cell anergy or unresponsiveness. Thus, 
CD8 T cells, by controlling the viral loads, allowed for the generation of a good CD4 T 
cell response and subsequent hypergammaglobulinemia. Supporting this, Recher et al. 
found virus-specific CD4 T cell responses, as measured by IFN-γ production, were 
diminished in the CD8- depleted animals (Recher et al., 2004). Thus, the LCMV-specific 
CD4 T cell response correlated with hypergammaglobulinemia but was inversely 
correlated with neutralizing Ab titer. To determine a direct causal relationship between 
CD4 T cells and hypergammaglobulinemia, an adoptive transfer study was performed 
where transgenic LCMV-specific SMARTA CD4 T cells were transferred into LCMV-
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infected CD8 KO mice. Mice that did not receive the CD4 T cell transfer did not 
experience hypergammaglobulinemia and rapidly generated LCMV-specific neutralizing 
Ab. Mice that received SMARTA cells had a robust hypergammaglobulinemia and did 
not generate neutralizing Ab. Parallel experiments were performed using a virus lacking 
GP61, the epitope recognized by SMARTA T cells. These mice also rapidly generated a 
neutralizing Ab response and had moderate hypergammaglobulinemia. These results 
show that virus-specific T cell help causes hypergammaglobulinemia but delays the 
formation of neutralizing antibodies. Recher et al. reasoned that during the course of an 
LCMV infection, they could enhance the onset of neutralizing Ab production by reducing 
the virus-specific CD4 T cell response. They reduced the CD4 T cell response by 
performing a partial Ab-mediated depletion of CD4 T cells in vivo before infection of 
mice with LCMV. By this method, a reduction in the number of virus-specific CD4 T 
cells resulted in a reduction of hypergammaglobulinemia and the earlier onset of 
neutralizing Ab. Recher et al. finally concluded that specific CD4 T cell help induces 
hypergammaglobulinemia and delays a neutralizing Ab response. These results, in 
combination with the results of Hunziker et al., suggest that this delay may be due to 
distraction of CD4 T cells by non-virus-specific B cells presenting viral antigen.  
These recent studies on virus-induced hypergammaglobulinemia in LCMV-
infected mice have concluded that the hypergammaglobulinemia was dependent on virus-
specific CD4 T cells and CD40L interactions, that it occurred more extensively in the 
presence of high antigen loads, that it required antigen presentation by B cells, and that it 
interfered with the generation of specific anti-viral neutralizing antibodies, perhaps 
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suggesting that T cells were distracted by antigen-presenting B cells of irrelevant BCR 
specificities (Recher et al., 2004; Hunziker et al., 2003). These studies were done 
concurrently with my own work and focused primarily on Ab production without 
examining the process of B cell activation and differentiation. Thus, the dynamics and 
magnitude of polyclonal B cell activation and proliferation under conditions of viral 
infection remained unclear.  
 
H. Thesis objectives.  I wanted to examine some of the interactions that occur 
between T cell and B cells during viral infections. To accomplish this, I performed 
adoptive-transfer studies, where B cells were coated with MHC class II-presented viral 
antigens and transferred into virus-infected hosts. These studies allowed me to define an 
MHC class II-restricted killing in vivo and polyclonal B cell activation during virus 
infection. 
 Hypergammaglobulinemia following viral infections has been described in 
humans and mice. This hypergammaglobulinemia seems to associate with viral infections 
that grow to high titer in infected hosts. In several instances, CD4 T cells were required to 
induce hypergammaglobulinemia.  Studies done in LCMV-infected mice concurrent with 
my thesis have shown that hypergammaglobulinemia, in addition to its association with 
high viral loads, is dependent on CD4 T cells, CD40-CD40L interaction, and presentation 
of viral epitopes on B cells. The hypergammaglobulinemia is inversely correlated with 
the virus-specific neutralizing Ab response and it was suggested that the 
hypergammaglobulinemia is caused by B cells that are not virus-specific.  These studies 
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focused primarily on Ab production without examining the process of polyclonal B cell 
activation and differentiation.  
Conditions transpiring in infections with high antigen loads may allow B cells to 
present viral antigens in a BCR-independent manner and become activated. This has been 
proposed to be the cause of hypergammaglobulinemia but the ability of these viral 
antigen-presenting B cells to become activated in vivo has not been formally tested. For 
my thesis, I questioned the fate of a polyclonal population of B cells presenting viral 
epitopes after adoptive transfer into virus-infected hosts. My thesis work shows that this 
polyclonal population of B cells has two fates. Some are killed in vivo by CD4 T cells 
(CHAPTER III). This work is the first evidence of MHC class II-restricted killing in vivo 
during viral infection. However, B cells that survive the cytotoxicity undergo a dynamic 
polyclonal activation manifested by proliferation, changes in phenotype, and Ab 
production (CHAPTER IV). This work is a careful examination of the activation of the B 
cells that are responsible for virus-induced hypergammaglobulinemia.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
A. Mice. C57BL/6J, Tnfsf1atml-Mak (TNFR-1-/-p55-/-), B6.129S7-
Ifngr1<tm1Agt>/J (IFN–γ KO), and B6Smn.C3-Tnfsf6gld/J (gld) mice were purchased 
from the Jackson Laboratory (Bar Harbor, ME). B6.SJL (Ly5.1) mice were purchased 
from Taconic Farms (Germantown, NY). B6.129P2-TCRB (αβTCR-/-), B6.MRL-
Tnfrsf6lpr (lpr), C57BL/6Ncr-Tnfrsf5tm1Kik (CD40-/-), and B6x129 TNF-α -/- and +/- mice 
were bought from the Jackson Laboratory (Bar Harbor, ME) and have been maintained in 
the animal colony at UMass Medical School. B6.Cg-IgHaThy-1aGpi-la/J (IgHa) mice, 
which express an allotypic immunoglobulin marker, were purchased from the Jackson 
Laboratory (Bar Harbor, ME). B6.SJL (Ly5.1) mice were purchased from Taconic Farms 
(Germantown, NY). MyD88-/- mice(Adachi et al., 1998) were kindly given to me by Dr. 
K. Alugupalli and then maintained in the animal colony at UMass Medical School.  The 
progeny of heavy chain VHSm7 knock-in and light chain Vk1AJk2 knock-in F1 mice 
(T,G)A-L, generated by Dr. Joan Press (Brandeis University, Waltham, MA), were 
kindly given to me by Dr. Robert Woodland (University of Massachusetts Medical 
Center, Worcester, MA). IFN-α/β R knockout (R KO) mice (also abbreviated as IFN-α/β 
R / , strain 129) were also provided by Dr. R. Woodland and then maintained in the 
animal colony at UMass Medical School.  
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B. Viruses, protein antigen, and mouse inoculation. Mice were inoculated 
intraperitoneally (i.p.) with 4 x 105 PFU in 0.1 ml of LCMV, strain Armstrong, passaged 
in baby hamster kidney (BHK21, American Type Culture Collection) cells in Dulbecco’s 
medium (Invitrogen, Carlsbad, CA) containing 10% fetal calf serum (FCS).  GP61-80 is 
an LCMV-encoded   I-Ab – restricted class II MHC peptide with  the amino acid sequence 
GLNGPDIYKGVYQFKSVEFD; NP309-328 is an LCMV-encoded I-Ab – restricted 
class II MHC peptide with the sequence SGEGWPYIACRTSVVGRAWE; GP118-125 is 
a subdominant LCMV-encoded Kb – restricted class I MHC peptide with the sequence 
ISHNFCNL, and HA209-224(Cauley et al., 2002) is an influenza virus strain A/x31 
encoded   I-Ab – restricted class II MHC peptide derived from the hemagluttinin protein 
with the sequence SLYVQASGRVTVSTRR. (T,G)A-L is a multivalent antigen with the 
following structure: poly-L-(Tyr, Glu)-poly-DL-Ala--poly-L-Lys. 
 
C. Preparation of cells. Single cell lymphocyte suspensions were prepared from 
spleens, peripheral blood, or bone marrow. In all cases erythrocytes were lysed using a 
0.84% NH4Cl solution. Spleens were crushed using frosted microscope slides in 
RPMI1640 (Invitrogen) and then filtered through nylon mesh. Peripheral blood was taken 
from the tail vein into heparinized tubes. Bone marrow was obtained from femur and 
tibia by removing both ends of the bone, followed by lavage with RPMI1640 
(Invitrogen). For organ harvesting and subsequent adoptive transfer, media was not 
supplemented. For organ harvesting at the termination of experiments, RPMI was 
supplemented with 10% FCS.  
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D. Antibodies and Reagents. In order to identify the type of donor target cells 
for some in vivo cytotoxicity assays, surface stains were performed as described below 
using fluorescently labeled mAbs specific for Ly5.1 (A20), I-Ab (AF6-120.1), B220 
(RA3-6B2), and CD19 (1D3), all purchased from BD PharMingen (San Diego, CA). For 
intracellular cytokine stains, the cells were stained for 30 min at 4°C with combinations 
of fluorescently labeled mAbs specific for CD4 (L3T4), CD8α (53-6.7) or CD8β (Ly-3), 
and IFN-γ (XMG1.2), all purchased from BD PharMingen, and for granzyme B (GB12), 
purchased from Caltag Laboratories (Burlingame, CA). 
For some in vivo cytotoxicity assays, CD4+ cells were depleted in vivo by i.p. 
inoculation of 0.5 mg of mAb GK1.5 (Wilde et al., 1983) on both two and one days prior 
to target cell transfer. Depletion of CD4 T cells was confirmed by cell surface stain for 
L3T4, a different anti-CD4 Ab. CD8α cells were depleted using 2.5 mg mAb Lyt-2 (2.43; 
ref. (Sarmiento et al., 1980) on both five and one days prior to target cell transfer. 
Depletion of CD8 T cells was confirmed by cell surface stain for CD8β (Ly-3). mAb 
GK1.5 (anti-CD4) was given to me by Dr. Kenneth Rock (UMass Medical School 
Worcester, MA) and mAb Lyt-2 (2.43) was prepared by me from ascites.  
For analysis of cells following adoptive transfer, single cell leukocyte suspensions 
were prepared. Following pre-incubation with 1 µl of Fc block (2.4G2) in 96-well plates 
containing 100 µl of fluorescence activated cell sorting (FACS) buffer (Hank’s Balanced 
Salt Solution [HBSS], 2% FCS, 0.1% NaN3), the cells were stained for 30 min. at 4°C 
with combinations of fluorescently labeled mAbs specific for donor cell markers listed 
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below, B220 (RA3-6B2), CD19 (1D3), I-Ab (AF6-120.1), Fas/CD95 (Jo2), CD4 (RM4-
5), all purchased from BD PharMingen, and IgM (R6-60.2), IgD (11-26), and GL-7, all 
purchased from eBioscience  (San Diego, CA). Biotinlyated peanut agglutinin from 
Vector Labs (Burlingam, CA) was used in combination with a streptavidin Pacific Blue 
conjugate from Molecular Probes (Carlsbad, CA).  Biotinylated monoclonal Ab 8A7 that 
recognizes the variable region of the heavy and light Ab chains of (T,G)A-L transgenic 
mice was generated by Dr. Joan Press and was kindly given to us by Dr. Robert 
Woodland. This Ab was also used in conjunction with a streptavidin Pacific Blue 
conjugate from Molecular Probes. Cells were washed and fixed in BD cytofix buffer for 
5 min. at 4°C.  
For some adoptive transfer experiments CD4+ T cells were depleted in vivo by 
i.p. inoculation with 0.5 mg of mAb GK1.5(Wilde et al., 1983) one day prior to and three 
days following adoptive transfer. Depletion of CD4 T cells was confirmed by cell surface 
stain with a different anti-CD4 mAb, RM4-5. Blockade of costimulation was performed 
by administering 0.5 mg of mAb to CD154, clone MR1(Noelle et al., 1992), i.p. one day 
prior to adoptive transfer.  
 
E. Flow cytometry. Freshly stained samples were analyzed using a BD 
Biosciences LSRII and FACS Diva Software, FACSCalibur and Cellquest Pro Software 
(San Diego, CA), or FlowJo (Treestar, Inc.) software.   
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F. Intracellular cytokine stain. LCMV peptide-specific, IFN-γ-secreting CD4+ 
and CD8+ T cells were detected using the Cytofix/Cytoperm Kit Plus (with GolgiPlug; 
BD PharMingen), as described previously (Kim and Welsh, 2004). Briefly, cells were 
incubated with 5 µM of synthetic peptide, 10 U/ml human rIL-2 (BD PharMingen), and 
0.2 µl of GolgiPlug for 5 h at 37°C. To visualize overall functionality of CD4+ and CD8+ 
T cells, cells were incubated with 1 µg of purified anti-mouse CD3ε mAb (145-2c11; BD 
PharMingen). Following pre-incubation with 1 µl of Fc block (2.4G2) in 96-well plates 
containing 100 µl of FACS buffer (HBSS, 2% FCS, 0.1% NaN3), the cells were stained 
for 30 min at 4°C with combinations of fluorescently labeled mAbs specific for CD4 
(L3T4), CD8α (53-6.7) or CD8β (Ly-3), and IFN-γ (XMG1.2), all purchased from BD 
PharMingen, and for granzyme B (GB12), purchased from Caltag Laboratories 
(Burlingame, CA).  
 
G. In vivo cytotoxicity assay. In vivo cytotoxicity was determined using 
splenocytes coated with peptide epitopes and differentially labeled with the fluorescent 
dye 5(6) carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, 
Eugene, OR), as previously described (Oehen et al., 1997). Splenocytes from naïve mice 
were separated and labeled in RPMI1640 (Invitrogen) with indicated peptides (0.5 µg/ml; 
45 min at 37°C, 5% CO2).  Populations were then labeled with different concentrations 
of CFSE (1µM and 0.4µM for two targets, or 1µM, 0.4µM, and 0.15µM for three targets) 
in HBSS (Invitrogen), combined, and injected i.v. into mice. Spleen lymphocytes were 
isolated 18 h later, and the ratio of CFSE low/CFSE high cells was determined by flow 
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cytometry. In order to identify the type of donor target cells for some assays, surface 
stains were performed as described below using fluorescently labeled mAbs specific for 
Ly5.1 (A20), I-Ab (AF6-120.1), Fas/CD95 ( Jo2), B220 (RA3-6B2), and CD19 (1D3), all 
purchased from BD PharMingen (San Diego, CA).  The percentage of specific killing 
was calculated as follows: (1 - (ratio immune/ratio naive)) x 100. Ratio = number of 
events LCMV peptide-coated target/number of events reference target.  
 
H. Plaque assay. LCMV titers were determined by plaque assay. Organ 
supernatants were obtained by grinding tissues in a mechanized mortar and pestle 
apparatus. The organ slurry was then spun for 20 min at 1000 x G at 4°C to remove 
cellular debris. Supernatants were collected and frozen at -80°C.  Vero cell (ATCC) 
monolayers, grown in 6-well plates (BD Biosciences), were infected with 10-fold 
dilutions of freshly thawed organ supernatants for 90 min at 37° C in MEM (Invitrogen). 
Monolayers were overlayed with a 1:1 mixture of 0.8% Seakem agarose (FMC 
Bioproducts, Rockland, ME) and 2x EMEM (Biowhitaker, Walkersvile, MD) 
supplemented with 6% FCS and antibiotics. The plates were then incubated and stained 
on day four with a 1% neutral red stain (Sigma) included in the 1:1 mixture of 0.8% 
Seakem agarose and 2x EMEM supplemented with 6% FCS and antibiotics. 
 
I. Adoptive transfer of antigen-loaded cells. Donor splenocytes containing B 
cells  were isolated, charged with an immunogenic peptide, labeled with CFSE ( 2µM ), 
and transferred i.v. into naïve or day  8 to 11 LCMV-infected mice, as previously 
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described(Kim et al., 2002). Briefly, splenocytes from naïve C57BL/6, naive αβTCR-/- , 
or naïve IgHa mice (all Ly5.2) were separated and labeled with 0.5 µg/ml peptide for 45 
min at 37°C, 5% CO2.  Populations were then labeled with 2 μM CFSE (Molecular 
Probes, Eugene, OR) and 2 x 107 cells were injected i.v. into Ly5.1+ C57BL/6 mice. At 
no time were these donor B cells exposed to fetal calf serum (FCS), as FCS exposure 
caused a background proliferation likely due to the serum antigens.  Six to seven days 
after transfer donor cells were identified and analyzed by flow cytometry, using 
fluorescently labeled mAbs specific for Ly5.1 (A20) or Ly5.2 (104) (BD PharMingen, 
San Diego, CA).   
 
J. Antibody and antigen specific ELISA. Enzyme linked immunosorbent assays 
(ELISA) were done using a modification of the method described 
previously(Szomolanyi-Tsuda et al., 1998). Briefly, polyvinyl 96-well plates (Falcon, 
Franklin Lakes, NJ) were coated with 100 µl of diluted anti-IgM, anti-IgG2aa, anti-IgG, 
or (T,G)A-L (1µg/ml in carbonate buffer), incubated overnight at 4° C, and then blocked 
with 5% non-fat dry milk in whey dilution buffer (PBS containing 4% whey and 0.5% 
Tween-20).  Serum samples (diluted in whey dilution buffer) were added for 2 hours at 
room temperature.  Bound Ab was detected by using biotin-conjugated Abs to the mouse 
IgMa allotype, IgG2aa allotype, or IgG (1µg/ml in whey dilution buffer) (BD 
Pharmingen), and streptavidin-conjugated horseradish peroxidase (1µg/ml in whey 
dilution buffer) (Vector Laboratories, Burlingame, CA).  Plates were developed using 
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3,3’,5,5’-tetramethylbenzidine tablets according to the manufacturers protocol (Sigma, 
St. Louis, MO), and absorbence was read at 450 nm using a microplate reader.  
 
K. Antibody and antigen specific ELISPOT. Enzyme linked immunospot 
assays (ELISPOT) were performed to determine ASC number. IgMa-, IgG2aa- and  Anti-
(T,G)A-L IgG and IgM secreting ASC numbers were measured by ELISPOT using a 
modified method for measuring influenza-specific ASC(Guay et al., 2004).  Multiscreen 
HA plates (Millipore, Bedford, MA) were coated with 100 µl anti-mouse IgM clone R6-
60.2, anti-Mouse IgG2aa clone 8.3 (both from BD Pharmingen) or (T,G)A-L (diluted to 1 
µg/ml in PBS) overnight at 4°C, and blocked the following day with 200 µL RPMI 1640 
(Invitrogen) containing 10% fetal calf serum (FCS) for 30 minutes at 37°C.  Cells were 
plated in duplicate at several dilutions in 200 µL RPMI 1640 containing 10% FCS and 
incubated for 4 hours at 37°C.  Bound Ab was detected using biotin-anti-mouse IgMa 
(clone DS-1, BD Pharmingen) or IgG2a (clone 8.3) diluted to 1 mg/ml in PBS containing 
1% FCS and 0.1% Tween-20, and by streptavidin-horse radish peroxidase (HRP, diluted 
to 1µg/ml in PBS containing 1% FCS and 0.1% Tween-20; Vector Laboratories). Plates 
were developed using 3-amino-9-ethylcarbazole (AEC) substrate (Sigma) according to 
the manufacturer’s protocol. For some assays streptavidin-ammonium peroxidase 
(Invitrogen) diluted to (1ug/ml as above) and was used in combination with BCIP/NBT 
substrates (Sigma) according to the manufacturer’s protocol. Anti-(T,G)A-L bound Ab 
was detected using anti-mouse IgG or IgM directly conjugated to ammonium peroxidase 
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(Southern Biotech, Birmingham, AL)  in combination with BCIP/NBT substrates.  Spots 
were counted using a dissection microscope. 
 
L. Statistical analysis Where appropriate, statistics were calculated by 
performing student’s t-tests with Microsoft Excel software. A difference was considered 
significant when p=<0.05. 
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CHAPTER III 
 
MHC CLASS II-RESTRICTED CYTOTOXICITY IN VIVO 
FOLLOWING LCMV INFECTION 
  
Antiviral MHC class II-restricted cytotoxic CD4 T cells have previously been 
described in vitro in cell cultures (Jacobson et al., 1984; Lukacher et al., 1985; Maimone 
et al., 1986; Hou et al., 1993). However, the detection of this cytotoxic function was 
deemed to be an artifact of in vitro culture (Bourgault et al., 1989). Cytolytic activity 
could be detected in vitro if CD4 T cells were intoduced to a strong polyclonal stimulus 
in vivo (Erb et al., 1990), but only recently was antiviral cytolytic activity detected 
directly ex vivo in freshly isolated cells (Appay et al., 2002).  
Despite a large amount of in vitro data, the existence of MHC class II-restricted 
killing in vivo was still in doubt at the initiation of my thesis work. Elimination of MHC 
class II epitope-expressing target cells in LCMV-infected mice would provide evidence 
that class II-restricted killing can occur during viral infection. The LCMV infection 
stimulates strong CD8 and CD4 T cell responses against a number of defined MHC class 
I- (Whitton et al., 1988; van der Most et al., 1998) and MHC class II- (Oxenius et al., 
1995) presented epitopes. The two MHC class II I-A -restricted epitopes for LCMV are 
NP309-328 and GP61-80 (Oxenius et al., 1995), and up to 10% of CD4 T cells can be 
specific to these epitopes during an acute infection in C57BL/6 mice(Varga and Welsh, 
1998a). Due to such a high frequency of effector CD4 T cells, LCMV infection of mice 
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provides an attractive model system to demonstrate MHC class II-restricted killing in 
vivo. In this chapter, I provide evidence for MHC class II-restricted killing in vivo by 
performing in vivo cytotoxicity assays in LCMV-infected C57BL/6 mice (Oehen et al., 
1997).  By using this approach, I am able to identify mechanisms used by cytotoxic CD4 
T cells to eliminate target cells in vivo, and in these assays MHC class II-expressing B 
cells that present viral antigens become targets for MHC class II-restricted killing.  
 
A. Elimination of LCMV MHC Class II peptide-coated target cells in 
infected animals. I first examined killing of GP61-coated targets in vivo by transferring 
Ly5.1 splenocytes into day 14 LCMV-infected congenic C57BL/6 (Ly5.2) mice. After 20 
hours in vivo, about 52% of the MHC class II high donor cells (lymphocyte gated) 
labeled with GP61 peptide were lost when compared to the reference influenza A HA209 
peptide-coated donor population (Fig. III-1A and Table III-1A).  In contrast to these 
results, GP61-coated MHC class II low donor cells in the same recipient mouse were not 
eliminated (Fig. III-1B and Table III-1A). In vivo cytotoxicity against class II high GP61-
coated targets was also observed at day 9 postinfection (Table III-1B). As a second 
approach for doing in vivo cytotoxicity assays, I used donor cells from αβ T cell KO mice 
in my assay. Due to the absence of T cells, most of the donor cells from αβ T cell KO 
mice constitutively expressed class II MHC and could be evaluated directly without 
staining for class II MHC in the in vivo cytotoxicity assay. This technique demonstrates a 
similar loss of the GP61-coated population when compared to the reference population 
(Fig. III-1C and Table III-1C, D). This killing was also seen when the CFSE label was 
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reversed such that the GP61-coated population was CFSE high and the reference 
population was CFSE low (killing of GP61-coated targets CFSE high = 48 % vs. killing 
of GP61 coated target cells CFSE low = 47%). A reduced level of cytotoxicity (16%) was 
seen after incubation for 6 hours in vivo compared to 48% killing seen after 20 hours. 
The time necessary to lyse targets may reflect the mechanism used to kill or it may 
represent the amount of time it takes for a CD4 CTL to find its target or hop from one 
target to another.  Lower levels of in vivo cytotoxicity were directed against the LCMV-
subdominant MHC class II epitope, NP309, at day 14 post-infection (Table III-1C).  
When αβ T cell KO donor cells were stained for expression of the B cell markers CD19 
and B220, 80% of the donor lymphocytes and 60% of the donor leukocytes based on 
forward and side light scattering profiles were double positive. By comparing the 
cytotoxicity between these B cells and all other lymphocyte-gated donor cells, B cells had 
a 53% loss of the GP61-coated population whereas none (- 2%) of the other donor cells 
were killed (Table III-1D). Taken together, these data demonstrate the existence of viral 
antigen-specific MHC class II-restricted killing in vivo.  
 
B. CD4 cell-dependent cytotoxicity. Since MHC class II-peptide complexes are 
recognized by CD4 T cells, I determined whether CD4 T cells were acting as the 
effectors by depleting hosts of CD4 cells using the monoclonal Ab GK1.5 prior to 
injection of the donor populations. CD4 depletion was highly effective, as shown in Fig. 
III-2. In naïve mice, equal numbers of the injected GP61- and reference peptide-coated  
 
 65
 
 66
populations of αβ T cell KO splenocytes were observed by flow cytometry (Fig. III-2, 
Day 0). At Day 14, a selective loss of the GP61-coated population was observed in 
LCMV-infected mice with an intact CD4 cell population (Fig. III-2, Day 14 LCMV, 
Table III-1E). In infected mice depleted of CD4 T cells two days prior to transfer, the 
GP61-coated targets were not eliminated, and their profiles resembled those in naïve 
mice in that the GP61-coated population was about equal in size to the reference 
population (Fig. III-2, Day 14 LCMV –CD4, Table III-1E). The amount of killing was 
reduced about 5-fold, from 41% in controls to 8% in CD4-depleted animals (Table III-
1E).  In a separate experiment, depletion of CD8α cells in vivo did not prevent the 
elimination of GP61-coated targets (Table III-1F). These experiments indicate that the  
killing of GP61-coated αβ T cell KO splenocytes is dependent on CD4 T cells and not 
CD8 T cells.  
 
 C.  The role of Fas-FasL interactions in MHC class II-restricted killing. 
Several effector mechanisms have been demonstrated in the lysis of target cells in vitro 
by CD4 T cells, including FasL, TNF-α, and perforin. In order to implicate a mechanism 
for CD4-directed MHC class II-restricted killing in vivo during the LCMV infection, I 
used splenocytes from Fas mutant lpr mice mixed with Ly5.1 splenocytes as donors and 
transferred these into either naïve or LCMV-infected mice. I was thus able to distinguish 
killing of Fas mutant lpr targets from wild type targets in the same mouse based on the 
congenic marker. Lpr targets were killed less efficiently than wild type targets (26 versus 
41%, respectively) (Table III-1G). A similar pattern was seen on day 9 of infection 
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(Table III-1H). These results suggested that engagement of Fas-FasL may be required for 
some but not all of the class II-restricted killing in vivo. To examine the role of FasL, I 
used αβ T cell KO splenocytes as donors and either C57BL/6 or FasL-mutant gld mice as 
hosts in my assay. αβ T cell KO splenocytes were killed less efficiently in LCMV-
infected gld hosts compared to LCMV-infected C57BL/6 hosts (16 versus 31%, 
respectively) (Table III-1I). These results complement the results using lpr targets and 
further indicate a role for Fas-FasL in some, but not all, of the MHC class II-restricted 
killing. Analysis of the intracellular cytokine profiles of gld mice revealed no deficiency 
in the frequencies of CD4 T cells producing IFN-γ (Fig. III-3) in response to stimulation  
by GP61, when compared to wild type mice. Additional analysis showed that Fas 
expression was selectively elevated on the remaining GP61-coated target B cell 
population (Fig. III-4). Those GP61-coated B cells that survived MHC class II-restricted 
killing had a higher mean fluorescence intensity (MFI) of Fas expression than HA209-
coated B cells or GP61-coated B cells from uninfected mice.  
 
D. The role of TNF-TNFR interactions in MHC class II-restricted killing. 
FasL and TNF-α can sometimes exert complimentary or redundant functions, and both 
have been implicated in CD4 T cell killing in vitro (Tite, 1990; Stalder et al., 1994). I 
therefore performed the class II killing assay using TNFR1 KO splenocytes as donors or 
TNF-α KO mice as hosts. TNFR1 KO target splenocytes were killed at the same level of 
their wild type counterparts (Table III-J), suggesting that TNF was not required for this in 
vivo cytotoxicity. Killing of wild type targets was observed in LCMV-infected TNF-α  
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KO mice (15±6%, n=5), though it was not as robust as in littermate controls (29±8%, 
n=5), but this difference could be attributed to significant differences in the number of 
GP61-specific T cells in vivo (1.6 x 106, n=2, in wild type vs. 7.6 x 105, n=2, in TNF-α 
KO).  
 
E. The role of perforin in MHC class II-restricted killing. I also examined 
MHC class II-restricted killing in perforin KO mice and found virtually no killing in six 
out of six perforin KO mice at Day 9, despite the presence of CD4 T cells that produced 
IFN-γ in response to GP61 (3.5±1% of CD4 T cells, n=6). Only one of four surviving 
mice at day 14 had >7% killing. These experiments, however, were complicated by the 
fact that perforin is needed for viral clearance, and the resulting high antigen load in vivo 
may cause immune suppression or may have competed for the cytotoxic CD4 T cells and 
result in reduced clearance of the transferred cell population. To reduce viral load in 
those assays, I transferred 5x105 GP33-specific P14 transgenic T cells into perforin 
knock-out mice 1 day prior to infection and assayed for class II-restricted killing on day 
14 post-infection. This treatment resulted in a 15-fold increase in leukocyte number over 
the normally lymphopenic perforin KO spleen, but failed to reveal in vivo class II-
restricted cytotoxicity (-12±3%, n=3). These results suggest a role for perforin in in vivo 
cytolysis, but a complete clarification of the role of perforin might be better analyzed in 
another system where perforin is not essential for the clearance of an acute infection. 
LCMV infection in perforin KO mice results in the establishment of a persistent state 
where CD4 T cell function is impaired and clonal exhaustion of CD4 T cells may occur 
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(Fuller and Zajac, 2003).  It is unclear whether perforin KO CD4 T cells have been 
clonally exhausted at the time these in vivo cytotoxicity assays were performed. 
However, preliminary results in assays of polyclonal B cell activation suggest that CD4 T 
cells from LCMV-infected perforin KO mice are still functional because they have the 
ability to induce the proliferation of GP61-coated B cells in vivo. Thus, CD4 T cells from 
perforin KO mice can interact with adoptively transferred B cells and may only be 
impaired in their ability to lyse these antigen-presenting B cells, leading to the conclusion 
that perforin is required for MHC class II-restricted killing.  
 
F. The role of CD40-CD40L interactions in MHC class II-restricted killing. 
CD40-CD40L interactions are vital for B cell activation. Mice that are incapable of 
signaling through CD40 may have an even greater level of MHC class II-restricted 
cytoxicity because the target B cell population will be missing a potent survival signal. 
To examine the role of CD40-CD40L interactions on class II-restricted killing, I 
performed MHC class II-restricted in vivo cytotoxicity assays in mice treated with 1.5 mg 
of anti-CD40L Ab clone MR1, which has previously been shown to block CD40-CD40L 
interactions in vivo(Noelle et al., 1992). The GP61-coated target population was 
eliminated in anti-CD40L treated mice at a similar frequency as untreated control mice 
(Table III-2A and C). I also performed MHC class II-restricted in vivo cytotoxicity 
assays using CD40KO target cells and again found no difference in specific lysis of 
GP61-coated CD40KO targets compared with WT targets (Table III-2B and D). 
Interestingly, despite equal levels of killing, CD40KO target cells did not upregulate Fas 
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expression (Fig. III-5), suggesting that engagement of CD40 on B cells is required for the 
upregulation of Fas seen in WT cells that survive MHC class II-restricted cytotxicity 
(Fig. III-4).  However, because GP61-coated CD40KO and WT B cells are eliminated at 
equal frequency, these results lead me to believe the CD40-CD40L interactions do not 
provide any additional survival signals that protect target B cells from CD4-mediated 
cytotoxicity.  
 
G. The role of interferon-gamma in MHC class II-restricted killing. IFN-γ is 
an antiviral cytokine that is produced by CD4 T cells during the acute LCMV 
response(Varga and Welsh, 1998a). LCMV Armstrong and WE replicate to higher levels 
in IFN-γ-depleted mice. (Moskophidis et al., 1994; Muller et al., 1994).  IFN-γ is also 
important for the clearance of other viruses, such as MCMV although in this system, the 
IFN-γ is produced by NK cells(Orange and Biron, 1996). I tested whether or not IFN-γ 
was involved in MHC class II-restricted killing by transferring IFN-γ R KO targets that 
were Ly5.2 positive and WT targets that were Ly5.1 positive into the same LCMV-
infected hosts. I found that IFN-γ R KO targets were killed at a similar frequency as their 
WT counterparts (55% vs. 49%, Table III-2E), lending strong evidence that IFN-γ is not 
the primary mechanism used by CD4 T cells to kill their targets nor does it provide a 
survival signal to targets. 
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H. Chapter summary.  Previous in vitro studies have shown that CD4 T cells 
can kill virus infected targets, but this MHC class II restricted cytotoxicity had never 
been shown to occur in vivo. It is reasonable to suppose that CD4 mediated cytotoxicity 
could be detected in vivo in infections that generate strong CD4 T cell responses. LCMV 
generates such a response. Using in vivo cytotoxicity assays, I specifically asked what 
would happen to MHC class II expressing cells that present viral antigens following 
adoptive transfer into LCMV-infected hosts.  
Approximately one day after adoptive transfer, there was a significant loss of the 
cells expressing the I-Ab -presented MHC class II epitopes GP61 or NP309 in LCMV-
infected mice compared to cells coated with a peptide from an unrelated virus. Thus, 
MHC class II-restricted killing can occur in vivo during viral infection. This killing is 
specific, because only virus-specific targets were eliminated and they were only 
eliminated in infected mice. Mice depleted of CD4 T cells prior to adoptive transfer did 
not eliminate virus-specific targets, suggesting that CD4 T cells are required for this 
killing. Depletion of CD8 T cells prior to adoptive transfer reveals that CD8 CTL are not 
involved. GP61-coated target cells were killed at a greater frequency than NP309-coated 
cells, and this may be a reflection of the number of cytotoxic CD4 T cells stimulated by 
these two epitopes. The frequency of effector CD4 T cells detected by intracellular 
cytokine staining in previous studies showed a similar dominance of the GP61 response 
over the NP309 response(Varga and Welsh, 1998a). GP61 is a more stimulatory epitope 
than NP309 for both the induction of CD4 CTL and cytokine secretion. 
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As a result of my studies I have also identified the mechanism of MHC class II-
restricted killing. As with previously published in vitro data, CD4 T cell-dependent 
cytotoxicity cannot be solely explained by one mechanism, but I have identified Fas-FasL 
interactions as one of the mechanisms and my results also strongly implicate a role for 
perforin. In vivo cytotoxicity assay using gld (FasL-deficient) hosts and lpr (Fas-
deficient) targets showed a reduced elimination of GP61-coated target cells in 
comparison to WT. Assays done in perfoin KO mice showed no elimination of GP61-
coated target cells despite the ability of perforin KO CD4 T cells to functionally interact 
with antigen-presenting B cells.  
 In these assays, B cells expressing viral antigens were targeted for lysis. Killing 
was restricted to MHC class II high cells that express the prototypic B cell markers B220 
and CD19. The killing of B cells in LCMV-infected mice opposes the proposition that 
antigen-presenting B cells can be induced during virus infection to undego polyclonal 
activation and cause virus-induced hypergammaglobulinemia. However, my results show 
cytotoxicity against B cell targets is incomplete and I will show in the next chapter that 
the surviving B cells that express viral antigens undergo polyclonal activation in LCMV-
infected hosts.  
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CHAPTER IV 
 
THE POLYCLONAL ACTIVATION OF B CELLS FOLLOWING LCMV 
INFECTION 
 
Hypergammaglobulinemia following viral infection has been observed for many 
years in humans and in mice (Rosen et al., 1977; Hutt-Fletcher et al., 1983; Racanelli et 
al., 2006; Lane et al., 1983; Li et al., 1990; Coutelier et al., 1988; Price et al., 1993; 
Stevenson and Doherty, 1998). This hypergammaglobulinemia is presumed to be the 
result of a polyclonal activation of B cells during viral infection. However, with the 
exception of the viruses like EBV that directly infect and transform B cells, polyclonal B 
cell activation as a result of virus infection has not formally been described. Recently, a 
correlation between the hypergammaglobulinemia associated with viral infection and 
high titer virus infection was made. Based on this correlation, a mechanism has been 
proposed to explain hypergammaglobulinemia where B cells, regardless of their antigen 
specificity, can take up viral antigen and present it to CD4 T cells which, in turn, induce 
Ab production in a CD40-dependent manner (Hunziker et al., 2003). If 
hypergammaglobulinemia is the result of polyclonal B cell activation, then B cells 
presenting viral antigens should be activated upon transfer into a virus-infected host by 
virus-specific CD4 T cells within that host. The MHC class II-restricted cytotoxicity 
described in chapter III seems incompatible with this concept because viral-antigen-
expressing B cells were killed by CD4 T cells. However, the results in chapter III show 
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that the CD4-mediated cytotoxicity against virus epitope-presenting B cell targets was 
incomplete and, in this chapter, I show that the surviving B cells become polyclonally 
activated in a CD4 T cell- and CD40-dependent manner which was also proposed to be 
responsible for virus-induced hypergammaglobulinemia. Unlike previous studies of 
virus-induced hypergammaglobulinemia, I provide a detailed analysis of virus-induced 
polyclonal B cell activation, including: proliferation, changes in phenotype, and Ab 
production. 
 
A. Proliferation of LCMV class II epitope-expressing B cells in vivo in 
LCMV-infected animals. The cytotoxicity against B cells expressing MHC class II 
antigens described in chapter III was incomplete. I asked what would happen to the 
remaining population of antigen-labeled B cells in LCMV-infected mice if they were left 
in vivo for several days. To examine the effects of virus infection on the antigen-
presenting naïve B cell population, CFSE-labeled splenocytes from αβ TCR KO (Ly5.2) 
mice were transferred into day 10 LCMV-infected or uninfected congenic B6.SJL 
(Ly5.1) mice. Day 10 was chosen because it is about at the peak of the LCMV-specific 
CD4 T cell response (Varga and Welsh, 1998a), because viral antigens are mostly cleared 
by this time, and because the incubation period of the donor B cell population in vivo 
would overlap with the timepoints described in chapter III . Because of the absence of T 
cells in αβ TCR KO mice, B cells were enriched in the donor population.  Six days after 
transfer, the CFSE profiles of donor Ly5.2+ B cells, identified by costaining with the 
prototypic B cell markers CD19 and B220, were compared between LCMV-infected  
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mice and uninfected mice. B cells coated with LCMV-specific peptides GP61 and NP309 
were induced to divide, as indicated by loss of CFSE label (Fig. IV-1a), and proliferate, 
meaning an increase in number (Table IV), in LCMV-infected mice but not in uninfected 
mice. Many of the cells that survived the predictable CD4 T cell-mediated cytotoxicity 
reported earlier in chapter III underwent division, demonstrating a high level of 
polyclonal activation apparently independent of BCR specificity. Calculations made by 
FlowJo software, which analyzes the CFSE profile based on the size of each peak, show 
that 64±11% of the remaining GP61-coated B cells and 19±4% of the remaining NP309-
coated B cells that survived the initial cytotoxicity went on to divide in vivo following 
transfer into LCMV-infected hosts. 
Donor cell division and proliferation reflected the CD4 T cell dominance 
hierarchy of these two LCMV-encoded peptides (Varga and Welsh, 1998a), as B cells 
coated with GP61 peptide proliferated more than those coated with NP309 peptide. This 
suggests that the proportion of B cells that proliferate may be affected by the frequency 
of CD4 T cells available to recognize the peptide.  Donor B cells coated with an LCMV 
MHC class I-restricted subdominant peptide GP92 were not induced to divide (Fig. IV-
1). This subdominant class I peptide was used as a control, as it did not sensitize B cells 
to in vivo cytotoxicity by CD8 T cells, in contrast to cells coated with the LCMV 
immunodominant class I peptides (Barber et al., 2003). Uncoated donor cells or donor 
cells coated with HA209, an irrelevant MHC class II-restricted peptide from influenza A 
virus, did not divide (Fig. IV-1) or proliferate (Table IV). Similar experiments using cells 
from C57BL/6 (Ly5.2) naïve mice as donors and Ly5.1 mice as hosts yielded similar 
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results. Also, GP61-coated donor B cells did not divide following adoptive transfer into 
influenza A virus-infected mice. In most experiments, peptide-coated B cells were 
adoptively transferred at day 9 or 10 of LCMV infection, but LCMV class II peptide-
coated B cells also proliferated if they were adoptively transferred into hosts at day 4, day 
7, day 14 and day 20 of LCMV infection, and they still proliferated, but to a lower 
degree, in the memory state at day 118 post-infection. Taken together, these data 
demonstrate a peptide-specific MHC class II-dependent polyclonal activation of B cells 
during LCMV infection.   
 The proliferation of the LCMV MHC class II peptide-coated B cells was 
evaluated in two ways. First, I calculated the number of donor B cells and found that 
there was an overall increase in the number of GP61 peptide-coated donor B cells in 
LCMV-infected mice compared to all other treatments (Table IV-1). Nevertheless, I was 
concerned that the “take” of transferred cells found following adoptive transfer may vary 
among LCMV-infected animals and uninfected animals. I thus also calculated the ratio of 
donor B cells to all other non-B donor cells to monitor the proportional increase of B 
cells within the donor cell population. These calculations show that the ratio of αβ TCR 
KO donor GP61-coated B cells to non B cells was about 10:1 in LCMV-infected mice, 
and the ratio of NP309-coated B cells to non B cells was 5:1, whereas the ratio of donor 
B cells to non B cells was about  2:1 in control groups. Similar results were obtained 
when C57BL/6 or B cell congenic (IgHa) donors were used; the ratio of GP61-coated B 
cells to non B cells was 3:1, in contrast to a 1:1 or 1:2 ratio in control hosts. C57BL/6 
donor cell ratios were lower than those for the αβ TCR KO donors because of B cell 
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dilution by donor T cells. These calculations clearly show that the overall number of 
LCMV MHC class II peptide-coated donor B cells increases in LCMV-infected mice. 
Further, the B cell number seen six days after transfer is likely an underestimate of the 
extent of proliferation, considering that about half of the B cells would be expected to die 
due to CD4 cell-mediated cytotoxicity within the first 24 hrs of transfer, as described in 
chapter III.  
 
B. Characterization of the phenotypic changes in polyclonally activated B 
cells. As these GP61-coated B cells underwent polyclonal activation in LCMV- infected 
mice, their surface phenotype changed in a manner characteristic of conventionally 
activated B cell populations (Monroe et al., 1983; Monroe and Cambier, 1983). These 
activated B cells up-regulated I-Ab (MHC class II) levels as they divided, and the entire 
dividing GP61-coated population had higher levels of MHC class II than uncoated B 
cells, with an average change in mean fluorescence intensity (MFI) of 48%, ranging from 
21%-68% (Fig. IV-2A, representive of 3 experiments, n=4). By their fifth division GP61-
coated donor B cells had also down-regulated IgD, with an average decrease in MFI of 
39%, ranging from 30%-43% (Fig. IV-2B, representative of 3 experiments, n=4), and up-
regulated IgM levels, with an average increase in MFI of 92%, ranging from 42%-126% 
(Fig. IV-2C, representative of 4 experiments, n=7).  Some of these B cells increased 
surface expression of the GC markers. For these GC markers, I compared activated 
GP61-coated B cells in LCMV-infected mice with uncoated B cells in LCMV-infected 
mice and found that the dividing population of GP61-coated cells stained higher for both   
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GL7, with a 129% average increase in MFI, ranging from 31%-300% (Fig. IV-2D, 
representative of 3 experiments, n=3) and peanut agglutinin (PNA), with a 140% average 
increase in MFI, ranging from 121%-161% (Fig. IV-2E, representative of 2 experiments, 
n=3), consistent with entry into GCs. 
As the LCMV-specific peptide-coated B cells divided, dynamic changes occurred 
in their surface BCR phenotype (Fig. IV-3). The least divided cells were IgD single  
positive. The next group, which had a moderate loss of CFSE, was IgD and IgM double 
positive. IgM single positive cells had an even greater CFSE loss. But the most divided 
cells, as determined by loss of CFSE, were negative for both IgD and IgM. This latter 
result could mean that those B cells have become plasma cells and down-regulated their 
BCR or it could mean that those B cells have class-switched to a BCR that is not IgM or 
IgD.  
Because I had previously seen that B cells coated with LCMV epitopes up-
regulated Fas expression (Fig. III-4), and because Fas was important for MHC class II-
restricted killing, I hypothesized that these surviving B cells would be Fas low, which 
may be the reason they escaped the CD4-mediated cytotoxicity. Instead, I found that the 
polyclonally activated GP61-coated population in LCMV-infected hosts had elevated 
levels of Fas in comparison to GP61-coated cells in uninfected mice or uncoated or 
HA209-coated B cells in LCMV-infected and uninfected hosts (Fig. IV-4). Furthermore, 
Fas expression seemed to increase as the GP61-coated B cells divided. These results are 
consistent with the other phenotypic changes seen in the dividing GP61-coated 
population in Figure IV-2 because it has previously been reported that up-regulation of  
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MHC class II and increased binding of GL7 or PNA coincide with Fas expression on GC 
B cells (Han et al., 1997).   
I next questioned if there was preferential activation of a particular splenic B cell 
subset or if both MZ and follicular B cells were equally induced to undergo polyclonal 
activation. I therefore stained GP61-coated B cells from LCMV-infected mice for 
expression of markers that are differentially expressed on these two populations: the 
complement receptor, CD21, and the low affinity Fc epsilon receptor, CD23. I found that 
about 75% of the transferred cell population was of the follicular phenotype 
(CD21intermediate, CD23+) whereas only 3.5% had a MZ phenotype (CD21high, CD23-
). A third population of B cells was found to be negative for both markers. All 
populations were capable of polyclonal activation in LCMV-infected mice (Fig. IV-5). 
 
C. CD4 cell-dependent proliferation. To determine whether CD4 T cells 
influenced the activation and proliferation of peptide-coated donor B cells, I depleted 
host mice of CD4+ cells with mAb GK1.5 one day prior to and three days following the 
adoptive transfer of peptide-coated αβ TCR KO splenocytes. The CD4 depletion was 
highly effective (Fig. IV-6 small boxes). Mice with an intact CD4 cell population (Fig. 
IV-6) had CFSE profiles similar to those previously shown in Fig. IV-1. In infected mice 
GP61-coated B cells divided better than NP309-coated B cells (Fig. IV-6). Again, no 
division was seen in uninfected mice.  In infected mice that were depleted of CD4 cells, 
no division was detected, and the CFSE profiles resembled those from uninfected mice  
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(Fig. IV-6). These experiments indicate that the peptide-specific division of GP61- and 
NP309- coated B cells was dependent on CD4 cells.  
Although most of these adoptive transfers of antigen-loaded B cells were 
performed at day 9 or 10 post-infection, when LCMV is normally cleared, there remains 
the possibility that some mice will have low levels of viral replication at the time of 
adoptive transfer which may play a role in polyclonal B activation. Furthermore, the peak 
in antiviral cytokine production also occurs around the time of adoptive transfer and it 
could be argued that polyclonal activation occurs as a result of a “bystander” cytokine 
effect and not via the direct recognition of viral antigens by CD4 T cells. The question 
remained whether virus-specific CD4 T cells alone were sufficient to induce polyclonal B 
cell activation. To address these possibilities, I questioned whether memory CD4 T cells 
could induce polyclonal B cell activation by transferring GP61-coated B cells into 
immune mice infected 118 days previously with LCMV. These LCMV-immune mice 
should have undergone all phases of the acute immune response to LCMV and should be 
left with a resting population LCMV-specific CD4 memory T cells. It is unlikely that 
active viral replication is occurring at 118 days post acute LCMV Armstrong infection of 
immunocompetent mice and it is unlikely that there would be any residual antiviral 
cytokines at 118 days post-infection (Welsh, 2000). GP61-coated B cells underwent 
several rounds of division in LCMV-immune mice after seven days in vivo, albeit, to a 
lower degree than in acute animals (Fig. IV-7). These results suggest that neither active 
viral replication nor virus-induced “bystander” cytokine effects are responsible for  
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polyclonal B cell activation and virus-specific memory CD4 T cells can induce 
polyclonal B cell activation.  
 
D. The role of CD40-CD40L interactions in polyclonal B cell activation. 
CD40 signaling is important for antigen-specific TD B cell activation, GC formation and 
memory formation (Borrow et al., 1996).  CD40 stimulation has also been implicated in 
the polyclonal activation of human memory B cells in vitro (Bernasconi et al., 2002; 
Traggiai et al., 2003) and for the hypergammaglobulinemia seen following high dose 
LCMV infection (Hunziker et al., 2003).  I tested the role of CD40 stimulation in my 
system by blocking CD40-CD40L interactions with mAb to CD40L. The CFSE profiles 
of donor cells from infected animals without anti-CD40L treatment demonstrated GP61-
specific polyclonal activation (Fig. IV-8A), but anti-CD40L treatment almost completely 
inhibited the B cell division. Further experiments were done using GP61-coated spleen 
cells from CD40 KO mice as donors for transfer into LCMV-infected mice. These B cells 
did not undergo polyclonal B cell activation (Fig. IV-8B).  Overall, these experiments 
identify CD40-CD40L interactions as a mechanism needed for the proliferation of GP61-
coated B cells. These results contrast with the in vivo cytotoxicity assays, where lysis of 
B cells was not blocked by this treatment (Table III-2, B and C).  
 
E. The role of MyD88-dependent signaling in polyclonal B cell activation. Toll like 
receptor (TLR) signaling has been proposed to be a requirement for T cell dependent B 
cell responses, but the role of TLR signaling during antiviral immune responses may be  
 94
 
 95
more complex than initially proposed (Pasare and Medzhitov, 2005; Guay et al., 2007). 
Work from our lab has shown that MyD88-dependent signaling is not required for acute 
T cell-dependent antiviral B cell responses but it is required for effectively generating 
long-term Ab responses (Guay et al., 2007).  TLR signaling has also been shown to 
induce polyclonal B cell activation of human memory B cells in vitro (Bernasconi et al., 
2002). Based of these observations, I questioned whether TLR signaling would be 
required for LCMV-induced polyclonal activation. I therefore transferred GP61-coated 
donor cells from mice deficient in MyD88, a signaling adaptor for most TLR signaling, 
into LCMV-infected hosts. B cells deficient in MyD88 underwent several rounds of 
division in LCMV infected mice, suggesting that MyD88-dependent TLR signaling 
within the B cell was not required for LCMV-induced polyclonal activation as manifested 
by proliferation (Fig. IV-9, upper panel). I next asked whether MyD88-dependent 
signaling was required in T cells for polyclonal B cell activation to occur. I transferred 
GP61–coated WT B cells into LCMV-infected MyD88KO hosts. The caveat to this 
experiment is that MyD88KO mice have a defective CD4 T cell response to LCMV 
(Zhou et al., 2008). Despite this defect, GP61-coated B cells divided several times in 
LCMV-infected MyD88KO hosts (Fig. IV-9, lower panel).  These results suggest that 
MyD88-dependent signaling is not required in B cells or T cells for virus-induced 
polyclonal B cell activation. 
  
F.  The role of type I interferon signaling in polyclonal B cell activation. 
LCMV induces a potent type I IFN  response 2 days post-infection, and LCMV replicates  
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to a higher extent in mice deficient in type I IFN signaling (Merigan et al., 1977; Muller 
et al., 1994; van den Broek et al., 1995). Type I IFN produced as a result of virus 
infection has been reported to enhance B cell responses. Type I IFN produced as a result 
of VSV infection was shown to mediate class switching to IgG and type I IFN 
produduced as a result of influenza virus infection up-regulated expression of the 
activation marker CD69 and costimulation ligand CD86 (Fink et al., 2006; Coro et al., 
2006). Influenza virus-induced type I IFN has also been shown to induce B cell activation 
in autoimmune disease-prone mice, resulting in a lupus-like disease. This disease was not 
seen after infection of type I IFN R KO animals bred onto the same genetic background 
(Jorgensen et al., 2007; Woods et al., 2007).  When given in conjunction with a protein 
antigen, recombinant type I IFN, enhances Ab production and GC formation(Le et al., 
2006) Based on these observations, I asked whether type I IFN signaling was important 
to induce polyclonal B cell activation during LCMV infection. I therefore transferred 
GP61-coated type I IFN receptor (type I IFN R) KO cells into LCMV-infected and 
uninfected hosts. Type I IFN R KO cells had a similar division profile as their WT 
counterparts (Fig. IV-10) indicating that type I IFN R signaling in B cells is not required 
for polyclonal activation to occur.  
 
G. The role of interferon-gamma signaling in polyclonal B cell activation. 
IFN-γ is an antiviral cytokine that is produced by CD4 T cells during the acute LCMV 
response (Varga and Welsh, 1998a). LCMV Armstrong and WE have higher viral 
replication levels in IFN-γ-depleted mice (Moskophidis et al., 1994; Muller et al., 1994).   
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IFN-γ is the major switch factor for IgG2a production by B cells and induces higher 
antigen presentation by B cells(Hawrylowicz and Unanue, 1988). The earliest reports 
using recombinant IFN-γ showed that it increased the proliferating capacity of resting B 
cells in vitro when given polyclonal stimuli like the TLR agonist lipopolysaccharide, 
though IFN-γ  could not induce proliferation on its own (Snapper et al., 1988). I therefore 
asked whether IFN-γR signaling was important for virus-induced polyclonal B cell 
proliferation by transferring GP61-coated IFN-γR KO donor cells into LCMV-infected 
hosts. The GP61-coated B cells underwent several rounds of division after six days in 
vivo (Fig. IV-11). Quantitatively, proliferation analysis of the CFSE profiles by FlowJo 
software did not reveal a major difference in the percentage of GP61-coated IFN-γR KO 
B cells that underwent cell division compared to GP61-coated WT B cells (47% versus 
50%, respectively). Subjectively, however, GP61-coated IFN-γR KO B cells appeared to 
have one or two fewer CFSE low peaks than WT B cells. More experiments using IFN-
γR KO need to be performed to elucidate this possible trend in cell division. Overall, 
IFN-γR KO B cells can indeed divide in LCMV-infected hosts and the proportion of IFN-
γR KO B cells that divide is similar to WT GP61-coated B cells. Thus, IFN-γR signaling 
is not absolutely required in B cells for polyclonal activation.  
 
H. Polyclonal activation of B cells from LCMV carrier mice. In the system of 
polyclonal activation of B cells described thus far, donor B cells were charged with 
peptide in vitro. I asked if B cells could be charged with viral antigens in vivo in the 
presence of high antigen loads and if this would lead to their polyclonal activation upon  
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exposure to helper CD4 T cells.  To test for this, I used B cells from mice that were 
congenitally infected with LCMV (LCMV-carrier mice).  These mice maintain high 
antigen loads in vivo, as they are immunologically tolerant to the LCMV infection and  
generate neither a CD4 nor CD8 LCMV-specific T cell response (Buchmeier et al., 
1980). B cells from Ly5.2+ LCMV-carrier mice were therefore harvested, labeled with 
CFSE, and directly transferred without any peptide treatment into LCMV-infected or 
uninfected Ly5.1+ hosts. I detected 1 x 104 PFU in the serum (Fig. IV-12b) and 1 x 105 
PFU of LCMV in the spleen (Fig.  IV-12c) of donor mice that were used in two of these 
experiments. Donor B cells from LCMV-carrier mice divided in acute-LCMV-infected 
hosts (Fig IV-12) at levels higher than uncoated non-dividing B cells from uninfected 
mice, but at a lower degree than in vitro LCMV peptide-charged B cells (compare Fig. 
IV-12 to Fig. IV-1).  This division occurred in 4 out of 5 donor groups tested, and in 
these mice 7-15% of donor B cells divided, as calculated by FlowJo software’s 
proliferation algorithm, which analyzes CFSE profiles according to peak size. Studies in 
several mouse strains have predicted the number of B cells secreting Ab to LCMV in 
carrier mice to be less than 1 out of 1000 (Moskophidis and Lehmann-Grube, 1984; 
Moskophidis et al., 1986), a frequency much lower than the 15% that became activated 
following adoptive transfer. Thus, this polyclonal B cell response must include 
predominantly cells whose BCR is not LCMV specific. It is possible that some of the 
dividing B cells were infected with LCMV, but the frequencies of those proliferating 
exceeded by about a log the reported frequencies (1.5%) of infected B cells in carrier 
mice (Homann et al., 2004), suggesting that at least some were cross-presenting antigens.   
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LCMV carrier B cells did not divide following transfer into previously uninfected 
animals, despite the fact that the hosts may have become infected with LCMV for 6 days 
due to carrier cell transfer. This lack of division between day 0 and day 6 is not surprising 
because the earliest detectable division for GP61-coated B cells was observed in the time 
period between day 4 and day 10 in LCMV-infected mice and it takes about 3 days for B 
cell division to get started (data not shown). Taken together, these results suggest that B 
cells, armed by high antigen levels in vivo, are able to undergo polyclonal activation 
without apparent triggering of their BCR.  
 
I. Antibody production by polyclonally activated B cells. The hypothesis 
proposed based on work done by Hunziker et al states that hypergammaglobulinemia is 
the result of an infection that grows to high titers in vivo (Hunziker et al., 2003). The high 
antigenic burden allows B cells, regardless of BCR specificity, to take up viral antigens 
and present them to virus-specific CD4 T cells, which, in turn, activate Ab production in 
a CD40-dependent manner. Thus, the antigen presenting B cells that become polyclonally 
activated following adoptive transfer into virus-infected hosts should be able to secrete 
antibodies. I, therefore, tested whether the polyclonally activated GP61-presenting donor 
B cells would secrete Ab. For these assays, I transferred GP61-coated and CFSE-labeled 
congenic antibody-allotype-mismatched (IgHa) donor B cells into LCMV-infected or 
uninfected Ly5.1 mice, which are IgHb. These donor B cells express a distinct epitope on 
their immunoglobulin molecules that allows for their detection by ELISA separate from 
host immunoglobulin. Seven days following transfer, the transferred IgHa donor B cells 
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displayed similar proliferation profiles as C57BL/6 and αβ TCR KO donor B cells (Table 
IV-1). Moreover, the cells coated with GP61 but not HA209 peptide secreted Ab, as IgMa 
was detected in the serum of LCMV-infected hosts that received GP61-coated 
splenocytes (Fig. IV-13A). IgMa Ab was not detected from the B cells implanted into 
uninfected mice, into hosts depleted of CD4 T cells, nor in hosts treated with anti-CD154 
(Fig. IV-13B). IgMa ASC were also detected with ELISPOT analyses but only when 
GP61-coated donor B cells were transferred into LCMV-infected hosts (Fig. IV-13C). 
The polyclonal activation of GP61-coated B cells following LCMV infection was 
therefore not limited to proliferation but also included Ab secretion. 
I next sought to determine if polyclonal activation of LCMV peptide-coated B 
cells would result in immunoglobulin class switching. Again, IgHa allotype-mismatched 
spleen cells were coated with LCMV or influenza peptides or left uncoated and then 
transferred into LCMV-infected and uninfected mice at day 10. Serum was harvested 
seven days later and tested for the presence of IgG2aa Ab by ELISA.  GP61- and NP309-
coated B cells produced IgG2aa Ab in LCMV-infected hosts but not in uninfected hosts 
(Fig. IV-14, upper panel). Unlike the results obtained for IgM secretion, one of two mice 
receiving uncoated IgHa B cells also had detectable levels of IgG2aa but these Ab levels 
were lower than those produced by GP61-coated cells. It is unclear why uncoated B cells 
that were not induced to divide or change phenotype would be induced to secrete Ab. 
One could speculate that Ab secretion by uncoated B cells could occur due to in vivo 
antigen uptake during the LCMV infection, similar to the proliferation of B cells taken 
from LCMV carrier mice which were also antigen labeled in vivo. This model would  
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predict that polyclonal B cell activation can induce Ab production without proliferation.  
It is also interesting to note that IgG2aa ASC were undetectable by ELISPOT analysis of 
cells isolated from the spleens of LCMV-infected mice that had received GP61-coated B 
cells. This result may indicate a homing of IgG secreting cells to another location such as 
the bone marrow. 
In light of these results I questioned whether these polyclonally activated IgG2a 
class-switched B cells home to the bone marrow, as has been previously described for  
virus-specific plasma cells (Slifka and Ahmed, 1996b). I therefore performed a similar 
adoptive transfer of antigen-coated B cells from the spleen into LCMV-infected or 
uninfected hosts and tested bone marrow for the presence of ASC. Bone marrow was 
harvested 10 days following adoptive transfer. ELISPOT analysis revealed that GP61-
coated B cells isolated from bone marrow of LCMV-infected mice secreted both IgG2aa 
and IgMa (Fig. IV-14, lower panel). In this experiment uncoated B cells did not produce 
Ab in LCMV-infected or uninfected mice. However, low levels of IgG2aa production 
could be detected when GP61-coated B cells were transferred into uninfected mice or 
when HA209-coated B cells were transferred into LCMV-infected mice. Neither of these 
treatments resulted in IgMa production and, in both cases, the IgG2aa production was less 
than half of the IgG2aa secreted by GP61-coated B cells in LCMV-infected hosts. The 
highest numbers of IgG-secreting cells were detected when GP61-coated B cells were 
transferred into LCMV-infected mice. These results show that the polyclonally activated 
population of B cells in virus-infected mice can mount a class-switched Ab response 
which can be detected by both serum Ab and ASC assays.  
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J. Polyclonal activation of a transgenic B cell population. In the previous 
sections of this chapter I described the virus-induced activation of a polyclonal 
population of B cells. I have shown that when these B cells are loaded with virus-specific 
MHC class II epitopes and transferred onto virus-infected hosts, they proliferate, change 
phenotype, and secrete Ab, just like B cells that are conventionally activated by specific 
signals through their BCR. It would be interesting to determine in future studies if some 
of the fine tuning that occurs when B cells are conventionally activated, such as SHM, 
also occurs during this polyclonal activation of B cells. Furthermore, the polyclonal 
activation of B cells has been hypothesized to result in the maintenance of memory B 
cells (Bernasconi et al., 2002). It would be interesting to determine in future studies if 
antigen-expressing memory B cells can become polyclonally activated following transfer 
into virus-infected hosts. Both questions have various technical challenges.  
The detection of SHM in B cells presents its own challenges. SHM is generally 
detected by sequencing the variable regions of activated B cells. This requires the 
identification of the DNA sequence of the germ-line-encoded antigen binding region of 
the BCR (Jacob et al., 1991). Changes that occur in the variable region sequence during 
SHM are monitored by DNA sequencing of B cells that are isolated after antigen has 
been introduced into the system. An alternative to this method of SHM detection is to 
have a B cell population whose antigen is known and whose germ-line-encoded variable 
region can be detected with an anti-idiotype Ab. With these, SHM could be measured by 
the ability of a B cell to bind its antigen but lose reactivity with the anti-idiotype Ab after 
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an immune response, suggesting that the variable region has changed from the germ-line-
encoded sequence.  
Other limitations make it difficult to detect memory B cell involvement in virus-
induced polyclonal activation. Memory B cells in mice cannot unambiguously be 
detected by flow cytometry; there is no way to determine if memory B cells are included 
in the proliferating population. Methods to detect memory B cells have relied on their 
ability to respond rapidly to secondary antigen stimulation but a rapid response may or 
may not occur after polyclonal activation.  The frequency of memory B cells generated 
after an LCMV-specific immune response has been determined to be 1 in 20,000 spleen 
cells, a frequency that would be difficult to detect in an adoptive transfer system (Slifka 
and Ahmed, 1996a).  
A transgenic B cell population may provide the necessary requirements to answer 
whether SHM is occurring and whether memory B cells are involved in the polyclonal 
activation of B cells after virus infection.  This transgenic system would provide a large 
population of B cells with known specificity and known BCR variable region. Thus, 
SHM could be detected by changes in the variable region of the BCR and the polyclonal 
activation of memory B cells could be measured due to the high frequency of memory B 
cells that would be found in transgenic mice after immunization with cognate antigen. I 
therefore performed preliminary studies to test for LCMV-induced activation of a BCR 
transgenic B cell population. This BCR transgenic B cell recognizes a multivalent epitope 
(T,G)A-L (Giorgetti and Press, 1994). (T,G)A-L is a synthetic peptide antigen which is a 
polymer of four amino acids: tyrosine, glutamic acid, alanine, and lysine. The (T,G)A-L 
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transgenic mouse is the result of an F1 cross between (T,G)A-L-specific heavy chain 
VHSm7 and light chain Vκ1AJκ2 knock-in parents.  Eighty percent of the B cells in F1 
mice recognize (T,G)A-L, and they can be identified with a mAb, 8A7, that recognizes 
the variable region of the (T,G)A-L-specific BCR. To test if these transgenic B cells 
could undergo polyclonal activation in LCMV-infected mice, I coated splenocytes from 
the transgenic F1 mice with GP61 and HA209 peptide and transferred these cells into 
LCMV-infected or uninfected B6.129 hosts. Two weeks after adoptive transfer, serum, 
spleen, and bone marrow were harvested and analyzed for donor cell division and anti-
(T,G)A-L Ab production. As seen with every polyclonal donor B cell population tested, 
only GP61-coated (T,G)A-L B cells divided in LCMV-infected host as defined by 
B220+, CD19+, and 8A7+ cells (Fig. IV-15). No other treatment resulted in donor cell 
division. Anti-(T,G)A-L antibodies were detected at highest levels in the sera of LCMV-
infected mice that received GP61-coated B cells. Lower levels of anti-(T,G)A-L 
antibodies could be found in the sera of uninfected and LCMV-infected mice that 
received HA209-coated cells or uninfected mice that received GP61-coated cells (Fig. 
IV-16A). Anti-(T,G)A-L ASC numbers followed a similar pattern. High numbers of anti-
(T,G)A-L ASC were detected by ELISPOT in the spleen and bone marrow of mice 
receiving GP61-coated B cells.  Lower numbers of ASC were detected in uninfected and 
LCMV-infected mice that received HA209-coated cells or uninfected mice that received 
GP61-coated cells (Fig. IV-16B and C). In summary, an antigen-presenting transgenic B 
cell population recognizing (T,G)A-L can be activated by LCMV in the same manner as 
a polyclonal population of B cells.   
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The transgenic population of B cells will be useful to answer questions about 
SHM and memory B cell involvement in virus-induced polyclonal activation. However, 
the results obtained with the transgenic B cell population also lend evidence to the fact 
that the virus-induced polyclonal activation of B cells is BCR independent. Using a  
polyclonal population of B cells, the high frequency of B cells that became polyclonally 
activated to proliferate and secrete Ab suggested that BCR specificity was not driving 
LCMV-induced polyclonal activation. There still remained the possibility that a 
conserved germ-line-encoded BCR motif may have low affinity interactions with viral 
antigens, as has been described for VSV(Pinschewer et al., 2004). Although no such 
interaction has been described for LCMV, these low affinity interactions could 
potentially drive polyclonal B cell activation. However, when one considers that the 
(T,G)A-L transgenic B cells were derived from a B cell that responded to a synthetic 
peptide antigen with repeat of four amino acids (poly-[tyrosine, glutamic acid] poly-
alanine, poly-leucine), it makes it difficult to believe that the (T,G)A-L-specific BCR 
could be cross-reactive with LCMV viral antigens or that BCR specificity plays some 
role virus-induced polyclonal B cell activation. Note that (T,G)A-L transgenic B cells do 
not divide unless they are coated with viral antigens. If (T,G)A-L-specific BCR were 
reactive with LCMV, all (T,G)A-L transgenic B cells would divide during infection. 
Therefore, the polyclonal activation of (T,G)A-L transgenic B cells indicates that virus-
induced polyclonal B cell activation occurs regardless of BCR specificity. 
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K. Summary of Chapter IV. In this chapter I describe the fate of the antigen-
presenting B cells that survive the MHC class II-restricted killing that was described in 
chapter III. These B cells presenting viral epitopes undergo a virus-induced polyclonal 
activation that is dependent on CD4 T cells and CD40-CD40L interactions. I provide a 
detailed analysis of the proliferation, phenotypic changes, and Ab production by these B 
cells. LCMV GP61- and NP309-coated B cells proliferate in LCMV-infected mice but 
not in uninfected mice. Uncoated B cells, B cells coated with LCMV MHC class I 
antigens, or B cells coated with an irrelevant influenza virus epitope do not divide in 
LCMV-infected animals. As the GP61-coated B cells divided, their phenotype changed in 
a manner characteristic of conventionally activated B cells that are entering a GC 
reaction. These GP61-coated B cells were stimulated to secrete antibodies in LCMV-
infected mice. The antibodies generated by polyclonally activated B cells were both IgM 
and class-switched IgG. Uncoated or HA209-coated B cells, which did not divide or 
change phenotype, did not produce the Ab to the same extent as polyclonally activated 
GP61-coated B cells. CD4 T cell depletion or CD40-CD40L blockade resulted in the 
absence of both proliferation and Ab production by GP61-coated B cells. B cells from 
LCMV carrier mice, where LCMV grows to high titers due to immunologic tolerance, 
undergo polyclonal activation in acute LCMV-infected hosts but not in uninfected hosts. 
Thus, the polyclonal activation of B cells shown in chapter IV complements the 
hypothesis proposed by Hunziker et al. and Recher et al. to explain the 
hypergammaglobulinemia caused by LCMV infection. My adoptive transfer study 
features a polyclonal population of B cells which present viral antigens regardless of 
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BCR specificity, it affirms the requirement for CD4 T cells and CD40L, it shows that the 
viral antigen-presenting B cells secrete antibodies, and it shows that B cells, under 
conditions of high viral load, take up and present viral antigens. However, unlike other 
studies which focused mainly on the hypergammaglobulinemia itself, the work presented 
in this chapter examines the B cells that are responsible for hypergammaglobulinemia. 
 By focusing on the B cells that are responsible for hypergammaglobulinemia, 
specific questions could be asked about the mechanisms involved in virus-induced 
polyclonal activation. In these studies I found that MyD88-dependent signaling, Type I 
IFN signaling and IFN-γ signaling are not required for polyclonal B cell activation.  I also 
show that polyclonal B cell activation can occur in a transgenic B cell population whose 
BCR is not crossreactive with LCMV. The polyclonal activation of this transgenic 
population shows that virus-induced polyclonal B cell activation is BCR-independent and 
these transgenic B cells will undoubtedly be of great use in future studies of virus-
induced polyclonal B cell activation.  
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CHAPTER V 
 
DISCUSSION 
 
This thesis examines some of the interactions that occur between CD4 T cells and 
B cells during a viral infection. I have described the existence of CD4-dependent killing 
of targets in vivo and the existence of polyclonal activation of B cells during LCMV 
infection. These two paradoxical fates occur as the result of BCR-independent viral 
antigen presentation on B cells. I used in vivo cytotoxicity assays that featured antigen-
presenting B cells as targets to show that MHC class II-restricted killing can occur in 
vivo after viral infection. MHC class II-restricted killing is CD4-dependent and specific 
to B cells that present cognate viral antigens.  CD4 T cells use Fas-FasL interactions and 
perforin as mechanisms for target cell lysis. I have also been able to characterize the 
dynamics and magnitude of a virus-induced polyclonal B cell activation through the use 
of a novel adoptive transfer system that also featured antigen-presenting B cells. 
Polyclonal B cell activation is CD4- and CD40L-dependent and specific to B cells that 
present cognate viral antigens. Virus-induced polyclonal B cell activation during LCMV 
infection was hypothesized by others during my thesis studies to cause 
hypergammaglobulinemia (Hunziker et al., 2003). My studies, which focused on the 
polyclonal activation of B cells rather than the phenomenon of 
hypergammaglobulinemia, have definitively shown the existence and requirements for 
virus-induced polyclonal B cell activation and also the phenotypic, proliferative, and 
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functional changes that polyclonally activated B cells undergo. These dynamic 
interactions that can occur between CD4 T cells and B cells during virus infections were 
not fully appreciated previous to the work presented in this thesis.   
 
A. The cytotoxic CD4 T cell response to LCMV. The results in chapter III show 
that CD4-dependent MHC class II-restricted killing occurs in vivo. The ability to lyse 
virus-infected cells is a function that has primarily been described for CD8 T cells. This 
cytotoxic function had been described in CD4 T cells but only in vitro and usually only 
following in vitro culture (Jacobson et al., 1984; Lukacher et al., 1985; Maimone et al., 
1986; Hou et al., 1993). One fate of the adoptively transferred antigen-presenting B cell 
population used in this thesis was an MHC class II-restricted elimination by CD4 T cells 
in vivo. By taking advantage of the LCMV system and the robust CD4 T cell response it 
induces, I was able to show by in vivo cytotoxicity assay the first evidence of MHC class 
II-restricted killing in vivo during viral infection. 
In vivo cytotoxicity assays using GP61- and NP309-coated target populations 
showed that only LCMV-specific cells are killed and only in LCMV-infected mice. The 
specific killing of LCMV class II peptide-coated target cells mirrored the dominance 
hierarchy of cytokine production induced by these two peptides, where GP61 induced 
more specific lysis than NP309. Killing was also restricted to MHC class II high cells and 
not MHC class II low cells. These results identify MHC class II high cells that present 
virus-specific epitopes as the targets for in vivo cytotoxicity. 
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The frequency of CD4 T cells that can secrete cytokines in response to LCMV 
peptide stimulation may correlate to the frequency of CD4 T cells that can lyse antigen 
presenting targets. GP61-coated target cells were killed at a greater frequency than 
NP309-coated cells (Table III-1). The frequency of effector CD4 T cells detected by 
intracellular cytokine staining in previous studies showed a similar dominance of the 
GP61 response over the NP309 response (Varga and Welsh, 1998a). GP61 is a more 
stimulatory epitope than NP309 for both the induction of CD4 CTL and cytokine 
secretion. However, this correlation between the frequency of cytokine-producing cells 
and cytotoxic CD4 T cells is not absolute. While GP61 remains dominant to NP309, 
specific lysis of antigen-coated targets was seen both at the peak of the CD4 cytokine 
response at day 9 of infection and several days later at day 14 post-infection, when the 
frequency of cytokine-producing CD4 T cells is reduced. One would think that the most 
killing would occur when the CD4 effector frequency was highest, but perhaps cytotoxic 
CD4 T cell frequency peaks at a different time post-infection than the cytokine response. 
These results may reflect a change in phenotype of CD4 T cells from cytokine producers 
to CTL or they may indicate that cytotoxic CD4 T cells and cytokine-producing CD4 T 
cells are two distinct subsets.   
CD4 CTL have been found in many model systems. In most cases, cytotoxic CD4 
T cells were only found in CD4 T cell lines or from isolated cells that had experienced 
simulation through in vitro culture (Bourgault et al., 1989). Eventually cytoxicity was 
seen directly ex vivo (Erb et al., 1990; Appay et al., 2002). Previous studies of MHC 
class II-restricted killing often found that CD4-mediated killing would only occur in the 
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absence of CD8 T cells, as if the CD4 CTLS were compensating for the lack of CD8 CTL 
(Hou et al., 1993; Williams and Engelhard, 1997). In the LCMV system, cytotoxic CD4 
T cell activity could be detected in vitro using splenocytes isolated from i.p. infected 
mice deficient in CD8 T cells because they lack MHC class I expression (Muller et al., 
1992). Intracranial (i.c.) LCMV infection in these mice led to the death of many infected 
mice and a profound weight loss in the surviving animals (Quinn et al., 1993). CD4 
depletion prior to i.c. infection prevented death and weight loss in these MHC class I 
deficient animals. Death induced by i.c. infection with LCMV in WT animals is mediated 
by CD8 CTL and the authors of this study suggested that in MHC class I KO mice, CD4 
T cells may substitute for CD8 CTL. Adoptive transfer of increasing numbers of LCMV-
primed CD4 T cells derived from these CD8-deficient mice induced a higher incidence of 
death in i.c. infected mice. This result suggested a causal relationship between cytotoxic 
CD4 T cells and disease in these CD8-deficient mice (Quinn et al., 1993). Similar to my 
results, the CD4 CTL isolated from LCMV-infected MHC class I KO mice relied on Fas-
FasL interactions to kill targets in vitro (Zajac et al., 1996). Inhibitors of Fas prevented in 
vitro lysis of target cells by CD4 T cells isolated from LCMV-infected MHC class I KO 
mice. Furthermore, CD4-mediated death of i.c. infected mice did not occur if the MHC 
class I KO mice were also deficient in Fas. It is noteworthy that these studies and my 
study in vivo both found cytotoxic CD4 T cell activity that relied on Fas-FasL 
interactions to eliminate targets. In my system, CD4 T cells were capable of killing in the 
presence of a normal CD8 T cell compartment (Fig. III-1 and 2). Using in vivo Ab 
depletion I found that CD4 cells were necessary and that CD8 T cells were not required 
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for MHC class II-restricted killing (Table III-1). This finding was critical because the 
GP61 polypeptide has a subdominant MHC class I H2Kb-restricted epitope GP70 within 
its sequence (Masopust et al., 2007).  
In many of my assays, B cells were used as the target cell for MHC class II-
restricted killing. LCMV does not infect a high frequency of B cells, but one wonders if 
MHC class II-restricted killing of B cells is an evolutionarily conserved mechanism to 
kill virus-infected B cells or other MHC class II presenting cells. Some viruses, most 
notably EBV, can infect B cells and CD4 CTL may be partially mediating clearance of 
this viral infection. Lending evidence to this theory, EBV-specific CD4 CTL can be 
generated from the blood of EBV seronegative donors when co-cultured with EBV-
infected B cells (Savoldo et al., 2002). The generation of CD4 CTL from seronegative 
donors suggests that CD4 CTL may have mediated clearance of EBV in these patients.    
The importance of this CD4–dependent cytotoxicity remains unclear, but the studies 
showing requirements for CD4 T cells or for class II MHC in the control of viral 
infections in vivo must now take this cytotoxic function into account.  
 
B. Mechanisms by which CD4 T cells kill their targets. MHC class II-restricted 
killing in vivo cannot be explained solely by one mechanism. This was also observed in 
previously published in vitro studies of MHC class II restricted killing (Tite, 1990; 
Stalder et al., 1994; Williams and Engelhard, 1996). Here I identify Fas/FasL and 
perforin as mechanisms responsible for killing. MHC class II-restricted killing in FasL 
mutated gld host mice occured but the killing of targets was at lower frequency than in 
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wild type mice (Table III-1). Importantly, I found that the number of cytokine-producing 
CD4 effector T cells was not reduced in LCMV-infected gld mice, a result which 
suggested that the reduction in killing in these mice was not due to differnces in virus-
specific CD4 T cell number (Fig. III-3). The reciprocal assay, using Fas mutant lpr 
targets in direct competition with WT targets, showed that Fas expression on the target 
cells was necessary for optimal lysis (Table III-1).  Thus, Fas-FasL interactions were 
identified as a mechanism used by CD4 T cells for MHC class II-restricted cytotoxicity in 
vivo.  This result was perhaps not surprising because Fas-FasL interactions were reported 
to be the mechanism used for lysis by CD4 cell lines (Janssens et al., 2003).  
Several studies using in vitro derived CD4 CTL have identified perforin as the 
major mechanism for MHC class II-restricted cytotoxicity (Grossman et al., 2004a; 
Williams and Engelhard, 1997; Williams and Engelhard, 1996; Yasukawa et al., 1993). 
In agreement with these in vitro studies, I found no evidence of MHC class II-restricted 
cytotoxicity in vivo in LCMV-infected perforin KO mice. The in vivo cytotoxicity assays 
performed in perforin KO mice showed no specific lysis of the GP61-coated population, 
even when P14 transgenic T cells were used to reduce viral loads.  However, preliminary 
data generated in LCMV-infected perforin KO mice that received P14 transgenic CD8 T 
cells revealed that these mice could induce polyclonal B cell activation. I originally 
hypothesized that, due to high Ag loads in perforin KO mice, CD4 T cells would be 
engaged with LCMV antigens and would not get the opportunity to encounter the 
transferred target cell population. However, because there is sufficient T cell help to 
induce polyclonal B cell activation, it appears that CD4 cells in perforin KO mice can 
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interact with the transferred target cell population. Thus, CD4-mediated killing in vivo is 
likely to include a role for perforin. The caveat remains that perforin KO CD4 T cells 
may require more time to encounter and kill B cell targets and specific lysis may only be 
detectable after several days in vivo. However, this elimination would be masked by the 
onset of division by polyclonal activation. Others have shown that CD4 T cells lose their 
ability to secrete IL-2 in LCMV-infected perforin KO mice, but cytotoxicity was not 
tested (Fuller and Zajac, 2003). It is possible that CD4 T cells also lose cytotoxic ability 
in perforin KO mice as a result of high antigen loads and clonal exhaustion. Despite these 
caveats, the fact that perforin KO CD4 cells can mediate polyclonal B cell activation but 
not B cell killing strongly suggests that these CD4 T cells are encountering B cell targets 
and are functional in vivo. Since my initial report on MHC class II-restricted cytotoxicity 
in vivo during viral infection, other groups have also published their own work on MHC 
class II-restricted killing in vivo (Santosuosso et al., 2005; Brown et al., 2006).  Studies 
of antiviral CD4 CTL in influenza infection have also identified perforin as the 
mechanism of killing (Brown et al., 2006). Based on these results and my own studies, I 
conclude that perforin and Fas-FasL interactions are both used by CD4 T cells for MHC 
class II-restricted killing in vivo during virus infection.  
When the B cell targets that survived the CD4 dependent cytotoxicity were 
stained for Fas expression, I found that the remaining GP61-coated target B cell 
population expressed high levels of Fas. Elevated Fas was not seen on HA209-coated B 
cells or GP61-coated B cells in uninfected mice (Fig. III-4). I had previously observed 
that Fas-FasL interactions were partially responsible for MHC class II-restricted killing, 
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and, therefore, I did not expect to find surviving LCMV antigen-labeled target B cells 
with high Fas expression. Nevertheless, these Fas-expressing B cells were not eliminated. 
These results may indicate that some antigen-presenting B cells had not yet encountered a 
CD4 T cell with cytotoxic activity or they may indicate that some B cells can escape Fas-
mediated killing. The expression of Fas without the induction of apoptosis has been seen 
in GC B cells which up-regulate Fas but do not require Fas expression to undergo 
apoptosis (Smith et al., 1995). In chapter IV I show that the B cells which survive the 
MHC class II-restricted cytotoxicity become polyclonally activated and display a 
phenotype consistent with entry into GCs (Fig. IV-2). The antigen-presenting B cells that 
survive the CD4-dependent cytotoxicity may be protected due to their polyclonal 
activation and entry into GC reactions. This hypothesis is supported by evidence that 
human GC CD4 T cells have been shown to suppress Th1 cell responses in vitro. This in 
vitro suppression seemed to be mediated by Fas receptor ligation on the Th1 cells and 
also cytokine-mediated suppression via IL-10 and TGF-beta secretion by GC CD4 T cells 
(Marinova et al., 2007). If these GC T cells are also able to suppress the cytotoxic CD4 T 
cell response in LCMV-infected mice, it would suggest that entry into GC as a result of 
polyclonal B cell activation prevents lysis of those B cells. Thus, the MHC class II-
restricted killing of B cells may occur in a lymphoid compartment or location distinct 
from polyclonal B cell activation. In addition to protection conferred by GC Treg-type 
cells, other factors may protect B cells from MHC class II-restricted killing. For CD8-
mediated killing, protection of APC target cells from granule exocytosis has been 
described where target dendritic cells that express serpin serine protease inhibitor 
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molecules can be protected from specific lysis by CD8 T cells (Medema et al., 2001; Bots 
et al., 2005). Serpin molecule expression in GC B cells has also been reported (Frazer et 
al., 2000; Paterson et al., 2007).  It is unclear whether or not these serpins could prevent 
CD4-dependent cytotoxicity but it remains a possibility and could potentially explain 
why some antigen-presenting B cell targets resist cytotoxicity.   
Production of IFN-γ and TNF by CD4 T cells does not appear to mediate MHC 
class II-restricted killing, because targets deficient in TNFR1 and IFN-γ receptors are 
killed at similar frequencies as WT targets when they present viral epitopes in LCMV-
infected animals (Table III-1 and 2).  Based on these results it can also be concluded that 
neither of these receptors provides survival signals to B cells that prevent lysis by CD4 T 
cells.  Similar results were obtained when CD40KO B cells were used as targets for MHC 
class II-restricted cytotoxicity (Table III-2). Although CD40 signaling was crucial for the 
polyclonal activation of B cells (Fig IV-8B), CD40 receptor signaling does not appear to 
provide a survival signal for B cell targets that prevents in vivo cytotoxicity.  
CD40KO target B cells were incapable of upregulating Fas but were still 
eliminated in in vivo cytotoxicity assays (Fig. III-5 and Table III-2). The observation that 
Fas was not up-regulated is perhaps not surprising, because CD40 signaling is required 
for the formation of GC, the site where B cells up-regulate Fas expression(MacLennan, 
1994a). However, if GC B cells are somehow protected from MHC class II-restricted 
killing, as hypothesized earlier, then CD40 KO B cells, which cannot form GCs, should 
be more susceptible to lysis. My results show that CD40 KO B cells are not more 
susceptible than WT B cells to MHC class II-restricted killing (Table III-2). Furthermore, 
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CD40 KO B cells cannot undergo polyclonal B cell activation (Fig. IV-8B). Combined, 
these results suggest that polyclonal B cell activation does not induce the expression of 
anti-apoptotic molecules that can prevent CD4 killing.  Other unknown factors must, 
therefore, be involved in the B cell fate decision. 
As described above, CD4 CTL activity was detected in MHC class I-deficient 
animals infected with LCMV (Quinn et al., 1993; Zajac et al., 1996).  Other studies using 
LCMV GP61-specific SMARTA Tg CD4 T cells have shown that these transgenic CD4 
T cells have cytotoxic ability ex vivo in chromium release assays (Oxenius et al., 1998a).  
This cytotxicity only occurred when the targets expressed MHC class II with bound 
GP61. Similar to my results, effector CD4 T cells isolated at day 8 and day 13 post-
infection both displayed similar lytic activity ex vivo. These SMARTA transgenic CD4 T 
cells, therfore, could be used to alter the frequency of CD4 T cell precursors to determine 
if cytotoxic function correlates with the number of CD4 T cells. A correlation would 
indicate that T cells, and not the B cells themelves, control the fate of antigen-presenting 
B cells during viral infection. Additionally, if two types of CD4 T cells (killers and 
helpers) can be defined phenotypically and separated, these SMARTA cells would be of 
great use in future studies to possibly generate responses that consist entirely of either 
CD4 T cell-mediated killing or polyclonal B cell activation.  
Based on previous in vitro studies of CD4 killing, it was speculated that cytotoxic 
CD4 T cells may play a role in the regulation of immune responses (Hahn et al., 1995). 
These studies proposed that CD4 CTL may be a type of Treg used to dampen the immune 
response. Similar to my results in LCMV infection, perforin and FasL have been shown 
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to be the effector mechanisms used by Treg-phenotype cells for specific lysis of B cells, 
allogeneic targets, and DCs (Janssens et al., 2003; Grossman et al., 2004a; Grossman et 
al., 2004b; Kawamura et al., 2006). Because CD4 killing can occur late in infection 
during the silencing or contraction phase at the end of an immune response, it could be 
speculated that CD4 CTL may provide a mechanism that eliminates MHC II high cells 
that are presenting viral antigens. Elimination of these cells would effectively stop CD4 T 
cell stimulation and may lead to the silencing of a CD4 T cell response.  In the GC 
reaction, antigen contact provided to B cells by FDC is required for the BCR signaling 
that maintains B cell turnover (MacLennan, 1994a). Perhaps CD4 CTL can eliminate 
these FDC or B cells, thus terminating GC reactions during the silencing phase of the 
immune response. However, results described earlier would suggest that GC CD4 T cells 
might prevent cytotoxicity in the GC (Marinova et al., 2007).  CD4 CTL activity is also 
detected during the peak of the immune response that is associated with a transient period 
of immune deficiency in LCMV-infected hosts. This correlation makes it tempting to 
speculate that CD4 CTL may play some role in AICD of Fas-expressing CD8 T cells 
(Nagata, 1997). In this case CD4 CTL would simply provide FasL to the AICD sensitive 
CD8 T cells.   
 
C. Analysis of the B cell population that undergoes polyclonal activation 
after LCMV infection. In chapter IV I demonstrate that, in the context of a viral 
infection in vivo, B cells presenting viral class II epitopes can be driven to proliferate and 
secrete Ab without any apparent viral engagement of the BCR.  Because such a high 
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proportion of the B cells proliferate, I conclude that either the BCR is not stimulated at all 
or else it is stimulated by very low affinity endogenous or self antigens. It appears that 
sufficient help and stimulatory signals are provided by helper CD4 T cells and CD40-
CD40L interactions to drive the B cell activation and differentiation. This contrasts with 
the classical models of T cell-dependent B cell activation, where the BCR is engaged by 
viral antigens and where this interaction leads to endocytosis of the viral proteins, which 
are processed and presented as peptides in the context of class II MHC molecules. In the 
classical model, CD4 T cells recognize and provide help to these virus-specific B cells, 
which get antigen-specific stimulation through their BCR,  and the B cells then 
proliferate and differentiate into plasma cells and memory cells (Rajewsky, 1996). 
Conditions transpiring in a virus-infected host may allow B cells that are not virus-
specific to present viral antigen and become activated without a strong BCR signal. This 
mechanism has been suggested for a presumed virus-induced polyclonal B cell activation 
as detected by hypergammaglobulinemia (Hunziker et al., 2003), but in chapter IV I 
formally describe phenotypic changes in naïve B cells and demonstrate high levels of 
activation and proliferation in vivo in the absence of apparent BCR stimulation.   
The findings in chapter IV clarify a potential discrepancy between the MHC class 
II-restricted killing described in Chapter III and work by Hunziker et al., who suggested 
that B cells could be passively charged with viral antigens and be stimulated by cognate 
CD4 T cells to produce Ab (Hunziker et al., 2003).  A consequence of this phenomenon 
was a hypergammaglobulinemia induced by high dose LCMV infection, where antigen 
was plentiful (Hunziker et al., 2003).  Seemingly at odds with that finding was my report 
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in chapter III showing that peptide-expressing B cells were killed by CD4 T cells during 
LCMV infection. I report in chapter IV that, on further examination,  there is a residual 
population of B cells that escape CD4 T cell-mediated cytotoxicity, and that these 
remaining B cells undergo a polyclonal activation, as shown by CFSE-loss proliferation 
assays, phenotypic changes consistent with entry into GCs, and Ab secretion. Although I 
have not clarified why some B cells die and others proliferate, my demonstrations of the 
proliferation and differentiation of B cells complement the conclusions of Hunziker et al, 
whose main focus was on the production of Ab.  Both studies showed that B cells 
presenting class II antigens can be activated by CD4 T cells in a CD40-CD40L dependent 
manner without a defined involvement of the BCR. A broad based polyclonal activation 
of B cells was proposed by Hunziker et al, and my studies show that most of the B cells 
that escaped cytotoxicity can undergo proliferation, a result inconsistent with a role for 
the BCR, where some B cells would be expected to proliferate more so than others.  My 
study also shows that without LCMV-specific class II peptide presentation, there is 
absolutely no B cell division, indicating that cytokines alone during an infection will not 
induce B cells to divide.  Thus, my experimental strategies not only demonstrate the 
phenomenon of polyclonal B cell activation, but also track in vivo the differentiation and 
proliferation of the B cells that are being polyclonally activated. The potential 
significance of this polyclonal activation is documented in the introduction to this thesis 
and by studies of others (Bernasconi et al., 2002; Hunziker et al., 2003; Traggiai et al., 
2003; Ludewig et al., 2004; Recher et al., 2004). Some examples of the potential 
significance of virus-induced polyclonal B cell activation include the maintenance of 
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memory B cells, the induction of self-reactive B cells, and the distraction of CD4 T cells 
from virus-specific B cells resulting in the delay of neutralizing Ab formation.  
 
D. The antibodies produced during virus-induced polyclonal B cell 
activation.  Virus-induced polyclonal B cell activation resulted in the production of IgM 
and IgG2a. The production of IgM is perhaps not surprising because IgM responses are 
thought to be more innate and may result from cytokine stimulation that activates the 
more innate-like B1 and MZ B cells. However, this IgM response produced in my system 
of polyclonal B cell activation was T cell-dependent and did not occur in the absence of 
CD4 cells or CD40 signaling (Fig. IV-9B and C). It should be noted that the IgM was 
produced only by GP61-coated B cells and only in LCMV-infected hosts. These data rule 
out the possibility that cytokine-activated innate-like B cells are responsible for the IgM 
production. 
The hypergammalobulinemia detected following high dose infection in other 
studies primarily consisted of IgG (Hunziker et al., 2003). In my system, I was able to 
detect IgG production from a polyclonal population of IgHa allotype-mismatched B cells 
as well as from (T,G)A-L Tg B cells that were polyclonally activated during LCMV 
infection(Figs. IV-14 and IV-16). Based on these results, the peptide-coated B cell 
population that I transferred into hosts would be able to contribute to virus-induced 
hypergammaglobulinemia.  
The fact that Tg B cells can divide and secrete Ab also provides evidence that 
BCR specificity does not play a role in this virus-induced polyclonal B cell activation.  
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A caveat to using transgenic B cells specific to (T,G)A-L is that the level of Ab produced 
by the transgenic B cells may be more affected by MHC class II-restricted killing than a 
polyclonal population of B cells. Preliminary data using (T,G)A-L transgenic B cells as 
targets for in vivo cytotoxicity assays revealed that the transgenic population is more 
susceptible to lysis by CD4 T cells than a polyclonal population of B cells. Thus, if cell 
number correlates with Ab production, the levels of Ab produced by the transgenic 
population will never reach the levels produced by polyclonal IgHa B cells.  Despite this 
caveat, this transgenic B cell system will provide a valuable source of donor B cells to 
explore SHM and memory B cell involvement in future studies of virus-induced 
polyclonal B cell activation  
IgG2a production by the polyclonally activated B cell population was expected, 
because IFN-γ is the switch factor for IgG2a and IFN-γ is produced in abundance during 
LCMV infection (Gessner et al., 1990). However, Figures IV-14 and IV-16 show that 
IgG was also produced by B cells that did not present LCMV epitopes. These B cells did 
not divide in LCMV-infected hosts but seemed to be able to produce antibodies, unlike 
GP61-coated B cells which proliferated and produced antibodies. It could be speculated 
that these B cells were activated by another mechanism such as TLR engagement, and the 
IFN-γ produced during the LCMV infection led to the enhancement of IgG production 
from these B cells, as has been previously reported in vitro (Snapper et al., 1988). This 
was not the case with IgM production but IgM production is not enhanced by IFN-γ 
signaling and TLR simulation (Snapper et al., 1988). Another alternative explanation is 
that B cells can take up viral antigens in vivo during acute LCMV infection and this leads 
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to Ab production. Results from the polyclonal activation of B cells taken from 
congenitally-infected LCMV carrier mice upon transfer into acute LCMV-infected hosts 
provide evidence that in vivo antigen uptake can occur and lead to polyclonal activation.  
It is important to note that in all cases where donor B cell IgG production was detected, 
the highest levels of IgG in the serum and the highest number of IgG secreting cells were 
found in LCMV-infected host mice that received GP61-coated B cells(Figs. IV-14 and 
IV-16), and in all cases, these GP61-coated B cells had undergone more proliferation 
than any other donor B cell type (Table IV-1).  
 
E. Implications of virus-induced polyclonal B cell activation. B cell activation 
is normally thought to require signals from the BCR, from CD40, and from cytokines 
secreted by activated CD4 T cells that recognize peptides displayed on B cell class II 
MHC molecules.  B cell activation can, however,  occasionally be driven through less 
conventional BCR-independent pathways such as through toll-like receptor (TLR) 
ligation or direct MHC class II signaling (Chen et al., 1987; Pasare and Medzhitov, 2005; 
Nashar and Drake, 2006). Although B cells which capture antigens with their BCR 
present peptides on class II molecules more efficiently, there is no barrier preventing B 
cells of other specificities to passively absorb and cross-present viral class II antigens, 
especially under cases of high viral antigen loads or persisting viral infections. Viral 
infection of B cells with irrelevant BCR specificities could also be a mechanism for B 
cell presentation of class II antigens.  
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Polyclonal activation of  B cells without BCR triggering has been reported in 
vitro with human B cells stimulated by TLR agonists or with CD4 T cell help(Bernasconi 
et al., 2002), but my observation in vivo shows that TLR signaling through MyD88  was 
not required within the B cell.  It should be emphasized that polyclonal activation could 
only be seen when B cells were presenting cognate viral antigen and that no other 
treatment ever resulted in any B cell division. 
For significant levels of virus-induced polyclonal B cell activation in vivo, there 
should either be a high enough antigen load to allow for the presentation of viral peptides, 
albeit probably inefficient, on the B cells or, alternatively, the infection of a high 
frequency of B cells by the virus. LCMV infects B cells poorly, so presentation of 
antigen from the high dose antigen environment may be a preferred mechanism in this 
system (Buchmeier et al., 1980). Neutralizing Ab responses to LCMV are poor under 
conditions of high dose inocula (Hunziker et al., 2003), and there may be a reduced 
efficiency of CD4 T cells providing help to the virus-specific B cells due to the 
distraction of the T cells by other B cells cross-presenting antigen. It is noteworthy also 
that an LCMV peptide (GP61) that induces a higher frequency CD4 T cell response 
elicits more polyclonal activation of B cells than a peptide (NP309) that induces a lower 
frequency CD4 T cell response (Fig.  IV-1), implying that CD4 T cell help can be 
limiting for both the BCR-non-specific as well as the BCR-specific B cell activation.  
Hypergammaglobulinemia is associated with a number of human viral infections, 
such as HIV, HCV, and EBV (Burgio and Monafo, 1983; Hutt-Fletcher et al., 1983; Hu 
et al., 1986; Martinez-Maza et al., 1987; Rosa et al., 2005). All of these infections can 
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lead to high antigen loads.  In the unique case of EBV infection, the direct virus-induced 
transformation of B cells (Kuppers, 2003) might be the cause for polyclonal B cell 
stimulation, but CD4 T cells may still assist in this activation if viral class II antigens get 
displayed on the cell surface. It is noteworthy that EBV-encoded LMP1 is a viral 
equivalent of activated CD40 (Kilger et al., 1998), shown to be important in my system 
of polyclonal B cell activation.  
The observation of polyclonal B cell activation has implications for autoimmunity 
and for the long-term maintenance of B cell memory and serum Ab titers.  Autoreactive 
B cells might take up viral antigens and be activated in this manner. Indeed, the 
generation of auto-antibodies is a common feature in human and mouse viral diseases 
(Hansen et al., 1998; Ludewig et al., 2004). Previous studies have also shown that a 
hemolytic anemia can be caused by LCMV-induced polyclonally activated B cells and 
that this process can be prevented by the depletion of CD4 T cells (Stellrecht and Vella, 
1992). I suggest that B cells reactive with red blood cell antigens may have become 
polyclonally activated because of their presentation of LCMV antigens to LCMV-specific 
CD4 T cells.  In fact, auto-antibodies with specificities that cause human disease have 
been isolated from mice during LCMV-induced hypergammaglobulinemia (Hunziker et 
al., 2003). 
What is not clear is why some antigen-pulsed B cells are killed by CD4 T cells 
and why others become polyclonally activated. These different fates may be determined 
by properties intrinsic to the T cell, as some T cells may help B cells while others kill B 
cells, or it may be a property of the B cell, with some B cells expressing higher levels of 
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anti-apoptotic molecules, or it may be a random stochastic process reflecting the number 
of T cell hits on a B cell. Results using CD40KO B cells as targets suggest that the fate 
decision is not due to entry in to GC. CD40KO B cells that cannot upregulate Fas, cannot 
form GC, and cannot undergo polyclonal activation were killed at about the same 
frequency as WT B cells. These results would suggest that survival signals in B cells 
induced by GC formation or polyclonal activation do not confer protection from MHC 
class II-restricted killing. These results may imply that different CD4 T cell subsets, 
killers and helpers, dictate the fate of B cells. However, preliminary results using 
transgenic B cells as targets for in vivo cytotoxicity assays suggest that there are B cell 
intrinsic factors which make B cells more susceptible to specific lysis.  Antigen-
presenting transgenic B cells, which are essentially a clonal population, were eliminated 
more than a polyclonal population of B cells espressing the same viral antigen in the 
same virus-infected mice. It may be that there are both B cell- and T cell-intrinsic factors 
which contribute to the fate of antigen presenting B cells in virus-infected mice. Of note, 
unlike in mice, activated human CD4 T cells express MHC class II (Lanzavecchia et al., 
1988) and one wonders whether CD4 T cells also could be subjected to polyclonal 
activation or MHC class II-restricted killing by a similar mechanism. 
Serum antibodies are secreted by activated B cells that have differentiated into 
plasma cells. Some plasma cells are short lived and contribute to clearance of the primary 
viral infection, whereas others are long-lived and can produce neutralizing Ab for several 
months or years following the primary infection (Manz et al., 1997; Slifka et al., 1998). 
One would think that, except in the case of persistent infection or secondary challenge, 
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serum Ab would disappear after a few months, but this is not the case, as titers can be 
maintained throughout a lifetime without obvious additional antigen stimulation (Manz et 
al., 1998). Several mechanisms have been proposed to explain this observation. One is 
that some plasma cells are long living and sufficient to maintain serum Ab (Slifka et al., 
1998). Another model suggests that persisting or cross-reactive antigen induces memory 
cells to divide and differentiate into plasma cells throughout an organism’s lifetime 
(Ochsenbein et al., 2000; Traggiai et al., 2003).  My results of virus-induced polyclonal B 
cell activation provide an additional explanation.  If memory B cells were polyclonally 
activated following viral infection, they may be induced to divide and secrete Ab. Over 
the course of an organism’s lifetime, the cumulative effect of constant exposure to new 
pathogens and other antigens and the subsequent even low level polyclonal B cell 
activation might lead to turnover of memory B cells and serum Ab maintenance. It has 
been shown that polyclonal activation of human memory B cells in vitro by TLR 
signaling or by mimicking CD4 T cell help with cytokines and CD40 engagement can 
occur in the absence of BCR signaling, and these signals were sufficient to sustain Ab 
titers in the culture fluid (Bernasconi et al., 2002; Traggiai et al., 2003). Interestingly, I 
found that MyD88 was not required for polyclonal activation of B cells during LCMV 
infection. 
 I have attempted to show that polyclonal B cell activation could lead to memory B 
cell stimulation by transferring GP61-coated influenza virus- or polyomavirus-immune 
splenocytes into LCMV-infected mice in some preliminary studies. With both donor 
spleen cell populations, the same frequency of GP61-coated B cells was induced to 
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proliferate as seen in Figure IV-1, where GP61-coated naive donor spleen cells were 
transferred: when influenza virus- or polyomavirus-immune spenocytes were transferred, 
GP61-coated B cells divided and uncoated or HA209-coated B cells did not. Due to the 
differences in proliferation amongst GP61-coated B cells and uncoated or HA209-coated 
B cells in LCMV-infected mice, I expected to see differences in the level of Ab produced 
by GP61-coated donor populations as I had seen when I used naïve IgHa donor B cells 
(Figs. IV-13 and IV-14). Despite the proliferation of GP61-coated cells, influenza virus-
specific Ab responses could not be detected in any mice regardless of treatment. This 
result could be explained by a low frequency of influenza virus-specific memory B cells 
in the spleen of influenza immune mice although these donor mice had detectable levels 
of anti-influenza serum Ab prior to adoptive transfer.  In contrast, polyomavirus VP1-
specific Ab was detected in both LCMV-infected and uninfected host mice and no 
discernable pattern could be detected with regard to LCMV antigen presentation by donor 
B cells. These results may be explained by the fact that polyomavirus can establish a 
persistent infection which could result in chronic B cell simulation (Moser and Lukacher, 
2001).  Similar studies have been done using mice infected with MHV68. Influenza 
virus-immune mice were infected with MHV68 and subsequently tested for 
hypergammaglobulinemia and anti-influenza Ab production (Stevenson and Doherty, 
1999). These mice experienced hypergammaglobulinemia as a result of the MHV68 but 
the level of anti-influenza Ab did not increase (Stevenson and Doherty, 1999). These 
results and my own preliminary studies would suggest that memory B cells are not 
stimulated by virus-induced polyclonal B cell activation. However, as previously 
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discussed, the use of a transgenic population of memory B cells in my adoptive transfer 
system will clarify whether memory B cells can indeed be polyclonally activated by virus 
infections.  
 
F. Conclusions. The data presented in this thesis help provide a better 
understanding of the interactions that occur between CD4 T cells and B cells during a 
viral infection. This thesis provides the first in vivo evidence for MHC class II-restricted 
killing, a function of CD4 T cells that was previously thought only to occur in vitro, and 
it describes a virus-induced polyclonal B cell activation, long thought to be the cause of 
hypergammaglobulinemia associated with human and murine virus infections. Several 
observations can be made from my studies where I used adoptive transfer systems to ask 
what would happen to viral-antigen-presenting B cells if they were transferred into virus-
infected hosts.   
The first set of observations is that MHC class II-restricted killing can occur in 
vivo and CD4 T cells are required for this killing. B cells that present viral antigens in 
virus-infected hosts are specifically eliminated by CD4 T cells. CD4 T cells use Fas-FasL 
interactions and perforin to kill target cells. The second set of observation is that those 
viral-antigen-presenting B cells that survive MHC class II-restricted cytotoxicity undergo 
a polyclonal activation manifested by proliferation and phenotypic change. Viral-antigen-
presenting B cells increase in number and display a GC phenotype. Complementing the 
previous reports of virus-induced hypergammaglobulinemia, the virus-induced polyclonal 
B cell activation is CD4 T cell-dependent and CD40-CD40L interactions are also 
 138
required. Virus-induced polyclonal B cell activation also results in Ab production, 
regardless of BCR specificity. B cells isolated from mice experiencing high viral loads 
also proliferate. Thus, virus-induced polyclonal B cell activation can explain the virus-
induced hypergammaglobulinemia. Both are caused by B cells, which regardless of their 
specificity, take up viral antigen and present it to CD4 T cells leading to their subsequent 
activation. The studies performed in this thesis provide a careful analysis of this process. 
Some of the mechanisms required for polyclonal B cell activation remain elusive, 
and an explanation as to why CD4 T cells kill some B cells and activate others is also still 
a mystery. However, the techniques and descriptions of MHC class II-restricted killing 
and polyclonal activation of B cells provided by this thesis should provide a base from 
which many future studies can be initiated. 
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